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Abstract 
 
Jennifer Carol Carter 
PPAR-γ Ligands and Adipocytes Regulate Expression of the Plasminogen Activator System 
in Breast Cancer 
(Under the direction of Frank C. Church, Ph.D.) 
 
There is a known association between a high-fat diet, excess adiposity and breast 
cancer development.  While the mechanism is not fully understood, the goal of this project 
was to evaluate the effects of dietary fatty acids and adipocytes on tumor cell motility, as it 
relates to the plasminogen activator system.  The plasminogen activator (PA) system is an 
important regulator of tumor cell motility, and is composed of the urokinase plasminogen 
activator (uPA), the urokinase cell surface receptor (uPAR) and the plasminogen activator 
inhibitor-1 (PAI-1).  While PAI-1 functions to inhibit uPA activity, elevated levels of PAI-1 
are paradoxically related to poor patient prognosis in breast cancer.  In addition to being 
increased in breast cancer, PAI-1 is also upregulated in obese individuals, potentially the 
result of adipocyte overexpression of PAI-1.  Although the literature is conflicting, elevated 
PAI-1 and obesity may be linked through the ligand activated transcription factor, 
peroxisome proliferator-activated receptor-gamma (PPAR-γ), the master regulator of 
adipogenesis.  This project began by characterizing the PA system in a series of cell lines 
which have been developed as an in vitro model of breast cancer progression.  A significant 
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difference in uPA expression was noted between the normal MCF-10A cells and the 
malignant MCF-10CA1 cells.  Using these cells we investigated the effect of various PPAR-γ 
agonists, including ciglitazone, arachidonic acid, an omega-6 fatty acid, and docosahexanoic 
acid, an omega-3 fatty acid, on cell motility.  Treatment with ciglitazone reduced both 
motility of MCF-10A and MCF-10CA1 cells and PAI-1 protein expression.  Using a PPAR-γ 
antagonist, we show that these effects are PPAR-γ independent.  In contrast, arachidonic acid 
treatment increased cell motility of MCF-10A cell in a PPAR-γ dependent manner.  To study 
the effect of adipocytes on epithelial motility we used primary human breast adipocytes, 
which express significantly more PAI-1 than their precursor cells.  Conditioned media from 
these adipocytes greatly increased both MCF-10A and MCF-10CA1 cell migration.  We 
provide evidence which suggests treatment with adipocyte conditioned media increases uPA 
activity on the cell surface and increases phosphatidylinositide-3 kinase activity.  The work 
presented in this dissertation is novel and provides evidence of a possible mechanism linking 
obesity, diet, and breast cancer development and progression, through the PA system.   
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Cancer is the second leading cause of death in the United States, accounting for an 
estimated 600,000 deaths in 2008 alone [1].  The American Cancer Society estimated over 
1.4 million new cases of cancer would be diagnosed last year [1].  Cancer develops from 
proliferation of a clonal cell population, through which the cells are being altered genetically 
and biochemically.  These cells are able to evade both cell cycle control and induction of 
apoptosis.  Cancer cells express a number of proteins that are also involved in angiogenesis.  
In addition to these events that support growth of a tumor in situ, cancer cells also possess the 
ability to degrade the extracellular membrane (ECM), allowing them to invade into 
surrounding tissue and vasculature, where they then travel to distant sites to form metastases 
(Figure 1.1).  Our lab is focused on the components of the plasminogen activator system, 
which is partially responsible for governing cell adhesion and lysis of the ECM.   
 
Breast Cancer 
 Carcinoma of the breast is the most common form of cancer diagnosed in women, 
with an estimated 178,000 new cases reported each year [1].  A number of factors influence a 
woman’s risk of developing breast cancer, including family history, age at first menarche and 
age at menopause, as well as a history of previous benign breast disease [2].  While not all 
breast lesions carry a risk of progressing to carcinoma, fibrocystic changes to the breast 
sometime do, such as atypical hyperplasia, proliferative breast disease, and ductal carcinoma 
in situ (DCIS) [2].  These precursor lesions may eventually develop into breast cancer, which 
will then degrade the ECM, allowing invasion into surrounding tissues. These metastases 
favor certain sites, such as the lungs, liver, and skeleton [2], often leading to patient death. 
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Obesity, Diet, and Cancer 
Obesity is a growing problem in the United States.  It is estimated that 65% of the 
adult population is overweight or obese [3].  Recent epidemiologic studies suggest obesity 
and diet are risk factors associated with developing certain cancers, including breast cancer 
[5,6].  In 1997, Huang, et al. showed a positive correspondence to adult weight gain and 
postmenopausal development of breast cancer [7].  Several reports suggest obesity and 
dietary fat intake are modifiable risks associated with breast cancer development [5,8] and 
patient prognosis following diagnosis [9].  Multiple studies have shown body mass index 
(BMI) to be correlated with several sex hormones [10--12], helping to explain the positive 
relationship between obesity and breast cancer risk.  Given the heterogeneity of the breast, 
which is made up epithelium, adipose tissue, and connective tissue (Figure 1.2), it is 
important to investigate the interactions of these stromal components and the breast 
epithelium.  
In addition to reports of obesity and cancer development, a number of studies suggest 
diet is a key player in cancer progression.  In terms of dietary fatty acids, there are many 
studies that suggest excess omega-6 (ω-6) polyunsaturated fatty acids are deleterious to 
health, while omega-3 fatty acids (ω-3) provide some benefits, specifically in terms of tumor 
biology.  Increased long-chain ω-6 fatty acids in adipose tissue of the breast correlates with 
the development of breast cancer [13].  In a mouse xenograft model, increasing ω-6 fatty acid 
results in increased prostate tumor growth and final tumor volumes [14].  By contrast, tumors 
in mice fed increased ω-3 fatty acids had increased apoptosis and decreased proliferation 
[14], suggesting a protective role of ω-3 fatty acids in tumor progression.  In breast cancer 
cells, gene expression is differentially regulated by ω-3 compared to ω-6 fatty acids [15].  A 
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number of animal studies also suggest a protective role for ω-3 fatty acids in breast cancer 
progression.  Recently, ω-3 fatty acids were found to inhibit HER-2/neu-induced breast 
cancer in transgenic mice [16].  Collectively, these studies provide information implicating 
dietary fatty acids in tumor regulation. 
 
Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) and PPAR-γ in tumor biology 
Peroxisome proliferator-activated receptor γ (PPAR-γ) is a member of the steroid 
hormone nuclear receptor superfamily.  It is involved in adipocyte development, glucose 
homeostasis, and is a target for insulin-sensitizing drugs for treatment of type II diabetes 
mellitus.  Both PPAR-γ gain of function and loss of function mutations are implicated in a 
number of human diseases, such as hypertension, atherosclerosis, and diabetes mellitus [17].  
As a nuclear receptor, PPAR-γ is a ligand activated transcription factor [18].  Once activated, 
PPAR-γ translocates to the nucleus and forms a heterodimer with retinoid X receptor (RXR).  
The DNA-binding domain of PPAR-γ then binds the response element (PPRE) located in the 
promoter of the target gene.  PPAR-γ then recruits co-activators to the gene.  In addition to its 
role as a transcriptional activator, PPAR-γ plays a role in transcriptional repression.  Recent 
research into the non-adipogenic function of PPAR-γ has shown PPAR-γ plays a part in 
repressing inflammatory cytokine production [19,20].   
PPAR-γ has been shown to have a number of ligands, both naturally occurring and 
synthetic compounds.  15-Deoxy-∆12,14-prostaglandin J2 (15d-PGJ2) is an endogenous 
ligand for PPAR-γ [21,22].  ω-3 and ω-6 polyunsaturated fatty acids have been also been 
shown to act as PPAR-γ ligands [23--25].  In addition to these natural ligands, a class of 
synthetic compounds, the thiazolidinediones, developed as antidiabetic drugs, are PPAR-γ 
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ligands [26,27].  These drugs act to activate PPAR-γ, sensitize tissue to insulin, and therefore 
increase glucose uptake. 
Clinically, PPAR-γ has been shown to be expressed in primary and metastatic breast 
adenocarcinoma cells [28].  Similar results have been seen in testicular cancer and colon 
cancer patient samples [29,30].  While the function of PPAR-γ in these tumors is not 
understood, in vitro data suggest PPAR-γ plays a role in tumor cell differentiation [28].  One 
group suggests PPAR-γ is preferentially induced and activated in prostate cancer compared 
to normal prostate epithelial cell, selectively inducing cell death in malignant cells [31].    
 
Plasminogen Activator (PA) System 
The role of the plasminogen activator (PA) system is to regulate fibrin clot lysis.  
Plasminogen is cleaved by a plasminogen activator to its active protease, plasmin.  Plasmin 
then proteolyses fibrin, restoring hemostasis.  Outside of this fibrinolytic pathway, the PA 
system also contributes to tumor cell invasion.  The serine protease urokinase plasminogen 
activator (uPA) cleaves the zymogen plasminogen to the active enzyme plasmin.  Plasmin 
then is able to degrade the extracellular matrix (ECM) directly or indirectly by activating pro-
matrix metalloproteinases, which then degrade the ECM [reviewed in 24].  Plasmin also 
activates more uPA, forming a feedback loop.  In addition to these roles, the cell surface uPA 
receptor (uPAR) plays a role in integrin mediated cell motility.  Bound to uPA, uPAR is able 
to bind various integrins, resulting in the rearrangement of the cytoskeleton, allowing cell 
motility [25,26].  Elevated levels of uPA is a poor prognostic indicator in a number of 
cancers, including breast [27,28].   
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The serine protease inhibitor (serpin) plasminogen activator inhibitor-1 (PAI-1), binds 
uPA, blocking the activation of plasminogen to plasmin.  PAI-1 also attenuated uPAR 
mediated cell adhesion and migration, forming the PAI-1/uPA/uPAR complex, which is 
quickly internalized.  uPAR is then recycled and PAI-1 and uPA are degraded.  Interestingly, 
elevated protein levels of the inhibitor PAI-1 has also been correlated to poor patient 
outcome in breast cancer [28,29].  This pathologic dysregulation of the PA system allows the 
tumor cells to move to surrounding blood vessels and lymphatics, invade and move to sites of 
distant metastases.  
 
Relationship of the PA system to PPAR-γ 
As it relates to the PA system, PPAR-γ has been implicated in regulating PAI-1 
[46,47].  Recently, a PPAR-γ response element (PPRE)-like consensus sequence was found 
in the promoter region of the murine PAI-1 gene [48].  Sawai, et al, reported that treating 
pancreatic cell lines with PPAR-γ agonists increases PAI-1 message and decreases uPA 
message, resulting in a decrease in cell invasion [49].  PPAR-γ may not directly modulate 
uPA message, but do so indirectly.  PPAR-γ inhibits NF-κB transcription [50,51], which has 
been shown to modulate uPA expression in breast cancer cells [52].  This offers an 
alternative method for PPAR-γ regulation of the PA system in cancer.  By blocking NF-κB, 
PPAR-γ is limiting uPA, thereby inhibiting cell migration and invasion. 
 
Dissertation Overview 
 The goals of this dissertation were two-fold.  The first aim of this dissertation was to 
investigate the role of PPAR-γ ligands, both synthetic and natural, in tumor cell biology and 
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regulation of the PA system (Figure 1.3).  In Chapter III, I provide characterization of the PA 
system in the MCF-10A family of cell lines.  In these cells, increased in vitro motility 
correlates with elevated uPA expression and increased phospho-Akt levels.  In Chapter IV, I 
describe the effects of various PPAR-γ ligands on both cell motility and PA system 
expression.  I provide data that suggests ciglitazone modulates PAI-1 expression and 
decreases cell motility independent of PPAR-γ activation.   
The second goal of this project was to study the effect of adipocytes on tumor cell 
behavior.  With regards to adipocyte mediated effects on breast epithelial cells, we saw a 
significant increase in cell motility in both MCF-10A and MCF-10CA1 cell lines when 
treated with conditioned media from adipocytes, but not their precursor cells.   
Overall, this dissertation represents the research I have taken part in for the last five 
years.  Serving as both a literature review and a review article, Chapter II gives an overview 
of the link between PPAR-γ and the plasminogen activator system in obesity and breast 
cancer.  The results presented in Chapters III, IV, and V provide valuable information about 
the regulation of the PA system in both normal and malignant breast epithelial cells, and the 
subsequent changes in cell motility.  The results discussed in Chapter V relate the importance 
of the tumor microenvironment, provide data linking adipocytes to an altered epithelial cell 
phenotype, and discuss future directions to take this project forward.   
  
 
 
 
 
  
8 
 
Figure 1.1.  Tumor proliferation, invasion, and metastasis.  Cancer cells proliferate at the 
primary site, evade apoptosis, then invade into the surrounding vasculature or lymphatics, eventually forming 
metastasis at distant sites.   
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Figure 1.2.  Breast tissue histology.  Breast tissue is heterogeneous, made up of a variety of cell types, 
including epithelial cells, adipocyte and fibroblasts.  www.proteinatlas.org/histology.php?content_id=37.  
Image used according to image usage agreement from Protein Atlas.   
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Figure 1.3.  Putative function of PPAR-γ in breast cancer.  Ligands activate PPAR-γ, resulting 
in a number of effects on the tumor cell.   
  
 
 
Chapter II 
 
Obesity and Breast Cancer:  
The Roles of Peroxisome Proliferator-activated Receptor-γ and  
Plasminogen Activator Inhibitor-1 
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Abstract 
Breast cancer is the most prominent cancer among females in the United States.  
There are a number of risk factors associated with development of breast cancer, including 
consumption of a high-fat diet and obesity.  Plasminogen activator inhibitor-1 (PAI-1) is a 
cytokine up-regulated in obesity whose expression is correlated with a poor prognosis in 
breast cancer.  As a key mediator of adipogenesis and regulator of adipokine production, 
peroxisome proliferator-activated receptor-γ (PPAR-γ) is involved in PAI-1 expression from 
adipose tissue.  We summarize the current knowledge linking PPAR-γ and PAI-1 expression 
to high-fat diet and obesity in the risk of breast cancer. 
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Introduction 
Breast cancer epidemiology 
Breast cancer is the most commonly diagnosed cancer in the female population and is 
second in cancer related deaths in the United States [1].  While the mortality has decreased 
slightly in recent years, the number of cases diagnosed annually has remained relatively 
steady.  According to the American Cancer Society, over 178,000 new cases are diagnosed 
each year, with an estimated 40,400 deaths from breast cancer in 2008 [1].  Ten-year survival 
rates of breast cancer patients are 81%, although higher in patients over 40, as women 
diagnosed at a young age typically have a more aggressive cancer that is less responsive to 
treatment [1].  Though both incidence rates and mortality rates have decreased in recent 
years, the healthcare costs and the emotional costs of breast cancer remain high.   
A number of risk factors are associated with development of breast cancer.  The 
greatest risk factors are age and gender, with females developing breast cancer 100 times 
more frequently than males [32].  As a woman ages, her risk of developing breast cancer 
increases, from 1 in 233 between the ages of 30-39 to 1 in 27 between the ages of 60-69.  
While age and gender are the greatest risk factors, there are also hormonal risk factors 
associated with breast cancer development, including age at first menarche, age at 
menopause, and lifetime exposure to estrogen [33,34].  Furthermore, a family history of 
breast cancer and a history of previous benign breast disease are risk factors associated with 
breast cancer [2]. 
 
 Breast anatomy  
The breast is a very heterogeneous tissue, composed of a number of different cell 
types.  Epithelial cells make up the parenchyma of the breast, forming the ducts and glands 
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involved in milk production, storage, and secretion [2].  Surrounding these epithelial cells is 
a network of fibroblasts, which generate the proteins of the breast connective tissue [2].  
Another key component of breast tissue is adipose, composed of mesenchymal precursor 
cells and the mature adipocytes [2].  In addition to energy stores, adipocytes synthesize and 
secrete a number of cytokines, which are involved in a number of pathogenic processes, 
including inflammation [35].   
Our interest in the adipose tissue of the breast stems from the understanding that the 
tumor microenvironment provides a number of signals and resources to the tumor cells, 
promoting proliferation, survival, and motility.  In that regard, adipocytes, or their precursor 
cells, may provide key factors in breast tissue needed for tumor development, progression, or 
even enable tumor cell invasion.  Additionally, several recent studies suggest a woman with 
dense breast tissue is more at risk for developing breast cancer [36--38].  Collectively, these 
results suggest that excess amounts of adipose in either the breast or other distant fat depots 
could provide a climate amenable to development of carcinoma of the breast. 
The overall goal of this chapter is to present evidence supporting the link between 
how a high-fat diet and obesity increases the risk of breast cancer.  We focus on the 
expression of the nuclear receptor peroxisome proliferator-activated receptor-γ (PPAR- γ) 
and the serine protease inhibitor (serpin) plasminogen activator inhibitor-1 (PAI-1).  
    
Tumor progression and metastasis 
 In order for a cancer cell to progress to a disease state, the cell must be able to 
proliferate and generate a clonal population, resulting in a tumor.  To do the most harm, 
cancer cells must possess the ability to survive and migrate from their site of origin.  Motility 
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allows these cells to move from primary sites, such as the breast, to distant metastatic sites.  
In terms of breast cancer, the most common sites of metastases are bone, brain and lung.  In 
order to move to distant sites, these cells must degrade the surrounding extracellular matrix 
(ECM) and invade into nearby blood and lymph vessels.  The plasminogen activator (PA) 
system allows for tumor cells to activate plasminogen, resulting in the active proteolytic 
enzyme plasmin and ECM degradation.  In breast cancer, this system is often dysregulated, 
resulting in migration and invasion of tumor cells into the surrounding vasculature and 
lymphatics. 
 Recently the tumor microenvironment has come into the forefront as a possible 
source of either help or hindrance to the tumor.  As mentioned previously, the breast is 
largely made up of fibroblasts, connective tissue, and adipose.  PPAR-γ is a key regulator of 
adipogenesis [39--41], and there is growing evidence of its importance in many 
pathophysiological processes [41--44].  PPAR-γ has been shown to be dysregulated in the 
obese population [45], and since obesity is a known risk factor for breast cancer 
development, PPAR-γ activity may play a role in breast cancer inhibition.  Several studies 
have suggested that activation of PPAR-γ inhibits cell proliferation and induces apoptosis in 
vitro [46--50].  PPAR-γ has been found to regulate PAI-1 expression in endothelial cells, 
smooth muscle cells, and pancreatic cell lines [51--53]. 
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The plasminogen activator system in breast cancer 
The role of the PA system is to regulate fibrinolysis and to promote pericellular 
proteolysis [54].  Plasminogen is cleaved by a plasminogen activator to its active serine 
protease, plasmin.  Tissue-type plasminogen activator (tPA) mediates plasminogen activation 
in the vasculature; plasmin then hydrolyzes fibrin, restoring hemostasis.  Outside of this 
fibrinolytic pathway, the PA system also plays a role in tumor cell invasion.  In the 
pericellular environment, the serine protease urokinase plasminogen activator (uPA) is 
primarily responsible for the cleavage of plasminogen.  Plasmin is then able to degrade the 
extracellular matrix (ECM) directly or indirectly by activation of pro-matrix 
metalloproteinases, which then degrade the ECM [55,56].  Plasmin also activates more uPA, 
forming a positive feedback loop that further supports invasion-linked processes.  In addition 
to these roles, the cell surface uPA receptor (uPAR) plays a role in integrin mediated cell 
motility.  Bound to uPA, uPAR is able to bind various integrins, resulting in the 
rearrangement of the cytoskeleton, promoting cell motility.  Elevated uPA is a poor 
prognostic indicator in a number of cancers, including carcinoma of the breast [57--60].  The 
serine protease inhibitor (serpin) PAI-1 binds to the active site of uPA, blocking the 
activation of plasminogen to plasmin.  PAI-1 also affects cell adhesion and migration though 
binding of the uPA/uPAR complex.  The PAI-1/uPA complex is recognized by lipoprotein 
related protein (LRP), a scavenger receptor, and is rapidly internalized; uPA and PAI-1 are 
then degraded and uPAR is recycled to the cell surface [61].  Since elevated PAI-1 levels are 
an indicator of poor prognosis in breast cancer, these data would suggest increased amounts 
of PAI-1 result in a deattachment of the cell from the ECM, allowing for enhanced cell 
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motility.  These tumor cells could then invade into the surrounding blood vessels and 
lymphatics, becoming metastases of the primary cancer. 
 
Urokinase plasminogen activator 
   Urokinase plasminogen activator (uPA) is a 53 kDa serine protease.  Initially a 
zymogen, pro-uPA is cleaved to the active form [62].  Though the physiological activator is 
unknown, in vitro a number of proteases can activate uPA.  In addition to protease cleavage, 
binding the uPA cell surface receptor uPAR can activate pro-uPA.  uPA functions to cleave 
plasminogen to its active protease plasmin.  In 1978, Verloes, et al, demonstrated inhibition 
of uPA resulted in tumor growth inhibition, implicating a pathological role for uPA [63].  
Since this discovery, uPA has been shown to be involved in tissue remodeling, inflammation, 
fertilization, embryogenesis, and tumor invasion [64,65].     
 
Urokinase plasminogen activator receptor 
 The cell-surface receptor for uPA (uPAR) is a 55-60 kDa protein.  It has no 
transmembrane domain; it is anchored to the cell surface by a glycosyl phosphatidylinositol 
anchor.  uPAR is required for the endocytosis of uPA/PAI-1 complexes and plays a key role 
in uPA activation.  Research has also shown uPAR mediates cell proliferation through 
activation of ERK/MAP kinase pathways following binding of uPA [66].  Examination of 
uPAR protein levels in several breast cancer cell lines showed a correlation with invasiveness 
in vitro [67].  In breast cancer patients, combined overexpression of uPAR, PAI-1 and uPA 
was shown to correlate with decreased survival [68].   
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Plasminogen activator inhibitor type-1 
PAI-1 is a glycoprotein of approximately 50 kDa [69] and a member of the serine 
protease inhibitor (serpin) superfamily of proteins [70].  PAI-1 binds the active site of tPA 
[71,72] and uPA, preventing cleavage of plasminogen.  Binding of PAI-1 to vitronectin (VN) 
stabilizes the protein in blood circulation [73].  While the physiological role of PAI-1 is to 
inhibit plasminogen activation, it is a poor prognostic indicator for a number of cancers, 
including breast cancer [74--76].  There is no single mechanism to explain why an elevation 
in PAI-1 protein results in decreased patient survival, but there are a number of studies that 
suggest alternative roles for PAI-1 outside of the traditional protease inhibitor role.  
Specifically, several studies indicate that PAI-1 promotes tumor growth through an inhibition 
of apoptosis [30,47,50].  PAI-1 has also been implicated in angiogenesis [77,78], increased 
cell adhesion [79], and increased migration [80].  In addition to the role of PAI-1 in breast 
cancer migration and invasion, it has been implicated in an inflammatory response [81], 
neutrophil recruitment, and in proliferation of smooth muscle cells [82].  Furthermore, 
increased PAI-1 levels have been associated with obesity [83--86], with recent reports 
suggesting the elevation in PAI-1 levels is the result of PAI-1 production from adipocytes 
[87--89].   
 
Obesity and breast cancer risk   
A number of risk factors are associated with breast cancer development (Table 2.1).  
While age and gender are the two predominant risk factors, some risk factors remain 
modifiable, such as diet and obesity [5,90,91].  Adult weight gain is correlated with increased 
breast cancer risk and is a poor prognostic factor [92].  The mechanism behind increased 
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incidences of breast cancer in obese individuals is poorly understood; however, the literature 
concerning this association has increased in recent years.   
Besides their traditional role as energy stores, adipocytes are now considered to be an 
important “endocrine gland”, expressing numerous proteins involved in several physiological 
and pathological responses [88,93].  Aromatase, the enzyme needed to activate estrogen, is 
one of the factors expressed by adipose tissue.  Recently it was suggested that stromal cells in 
the adipose tissue, not adipocytes, express aromatase [94--97].  Elevated aromatase in the 
breast correlates to elevated levels of estrogen in the breast [95].  It is hypothesized this is a 
key reason for the increased risk of developing breast cancer in obese postmenopausal 
women.   
 Another factor expressed in the adipose tissue is the hormone leptin.  In obese 
individuals, leptin is over expressed [98].  In vitro, leptin has been shown to increase cell 
motility and decrease cell apoptosis in breast cancer cell lines [91,99].  The mature adipocyte 
also expresses adiponectin.  As opposed to the over expression of leptin in obese individuals, 
adiponectin is down regulated [35,100].  Grossman, et al, showed the balance of adiponectin 
and leptin mediated breast cancer cell growth in vitro [101].  Studies have shown an anti-
tumor effect of adiponectin in breast cancer.  Treating cells with adiponectin decreases cell 
motility and induces apotosis [102].  Furthermore, adipocytes express several chemokines 
involved in the inflammatory response.   
A number of other adipokines are associated with cancer progression and metastasis, 
including PAI-1 [88,89,103].  As stated previously, obese individuals have elevated serum 
levels of PAI-1 [83,104].  Interestingly, one study found an inverse relationship between 
adiponectin and PAI-1 expression in overweight and obese women [81].  With elevated 
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plasma levels of PAI-1 from the adipose tissue, it is possible obese women are more prone to 
developing breast cancer and having a more aggressive disease.  Prostate cancer cell growth 
in vitro is enhanced by this cancer cell-adipocyte communication; thus, it is interesting to 
speculate that breast cancer cell-adipocyte interactions would behave in a similar manner. 
 
Peroxisome proliferator-activated receptor-gamma 
The master regulator gene of adipogenesis is PPAR-γ, a member of the nuclear 
receptor super-family [39,105].  Mice null for PPAR-γ are embryonic lethal, suggesting 
PPAR-γ is essential for normal mouse development.  PPAR-γ is a ligand activated 
transcription factor.  Upon binding of the ligand, PPAR-γ translocated to the nucleus and 
heterodimerizes with RXR.  PPAR-γ binds to the target gene at a PPAR response element 
(PPRE), where it initiates transcription through the recruitment of transcriptional machinery.  
Loss-of-function and gain-of-function mutations of PPAR-γ have been implicated in a 
number of disease processes, primarily type-2 diabetes mellitus, or insulin resistant diabetes 
[106].  The thiazolidinedione family of drugs works to activate PPAR-γ, restoring insulin 
sensitivity to tissue, upregulating free fatty acid uptake by adipocytes, and altering expression 
of adipokines [107,108].  PAI-1 expression is known to be regulated by PPAR-γ, though the 
literature is conflicting, suggesting PPAR-γ down regulates PAI-1 expression [109--111], 
while others suggests PAI-1 is upregulated by PPAR-γ agonists [52,53,112].  As 
adipogenesis is regulated by PPAR-γ, it has been postulated that obesity and the associated 
adipocyte pathology is due to a down regulation of PPAR-γ activity, either through mutation, 
phosphorylation or methylation [113--115].  While PPAR-γ is required for adipocyte  
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Table 1.1- Relationship between obesity, PPAR-γ, fatty acids and increased risk of breast 
cancer 
Component Association with 
obesity 
Association with 
breast cancer 
Primary source 
 
 
PAI-1 
  Breast epithelial 
cells, endothelial 
cells, smooth muscle 
cells, macrophages, 
tumor cells, 
adipocytes 
 
uPA 
 
Unknown 
 Tumor cells, 
epithelial cells 
 
 
uPAR 
 
Unknown 
 
 Monocytes, 
neutrophils, epithelial 
cells, tumor cells 
 
TNF-α 
 
 
 Macrophages, 
adipocytes, 
lymphocytes 
Aromatase   Breast epithelium 
ovaries, adipocytes 
Leptin  
 
 Adipocytes 
Adiponectin  
 
 Adipocytes 
PPAR-γ   Adipocytes, tumor 
cells 
ω-3 FA  
 
 Diet 
ω-6 FA   Diet 
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differentiation under normal conditions, PPAR-γ serves to regulate cell size and transcription 
of adipocyte specific genes [40,116]. One hallmark of obesity is elevated levels of 
inflammatory cytokines.  One way PPAR-γ works to regulate transcription is by blocking 
transcriptional machinery from binding target genes, resulting in a down regulation of gene 
expression.  In this manner, PPAR-γ negatively regulates several genes, including NFκB, a 
key transcriptional factor involved in numerous disease processes, including inflammation 
[20].   
Since PPAR-γ regulates adipocyte differentiation and normal function, PPAR-γ 
malfunction may play a role in tumor development.  Several studies have shown PPAR-γ  is 
expressed in a variety of tumor types, including pituitary tumors [117], ovaries [118], 
prostate [28,46], colon [119], and breast [28].  While the in vivo role of PPAR-γ in these 
tumor cells is unknown, in vitro data suggest PPAR-γ activation can induce apoptosis [50] 
and promote terminal differentiation of the breast tumor cells [28].  These findings supported 
a clinical trial testing troglitazone as a new chemotherapeutic agent in breast cancer, which 
was terminated when troglitazone was taken off the market for severe liver toxicity [120].  
More recent clinical trials have looked into the chemotherapeutic effects of two 
commercially available PPAR-γ agonists.  A Phase-I trial investigating rosiglitazone 
treatment in conjunction with the antineoplastic agent bexarotene found the maximum 
tolerated dose in patients with refractory cancers [121].  A Phase-II trial treating patients with 
high-grade gliomas with combination therapy of pioglitazone and the COX-2 inhibitor 
rofecoxib showed moderate activity, which was tolerated well by the patients [122].  The 
results of recent clinical trials with PPAR-γ agonists suggest the promise of new adjunctive 
combination chemotherapies for cancer patients.     
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Diet, PPAR-γ, and cancer development 
Recent epidemiologic studies suggest diet may also be associated with developing 
certain cancers.  In 1997, Huang, et al., showed a positive correspondence to adult weight 
gain and postmenopausal development of breast cancer [7].  These results and others suggest 
obesity is a modifiable risk factor for breast cancer development.  More recently, a study 
showed body mass index (BMI) to be correlated with several sex hormones, helping to 
explain the positive relationship between obesity and breast cancer risk [6].  Adult weight 
gain has also been associated with an increased risk of breast cancer, particularly in women 
not on hormone replacement therapy [123--125].   
In addition to reports of obesity and cancer development, a number of studies suggest 
diet is a key player in cancer progression.  Increased fat intake is a risk factor for a number of 
cancers, including breast, prostate, and colon.  While the mechanism is not fully understood, 
dietary fats have been implicated in tumor progression.  Dietary fats, specifically poly-
unsaturated fatty acids (PUFAs), are certainly involved in the inflammatory process 
[126,127], which is linked to cancer cell motility and survival.  PUFAs include the omega-3 
(ω-3) and omega-6 (ω-6) classes of dietary fatty acids, both of which play essential roles in 
normal physiology.  Consumption of ω-3 fatty acids, specifically, eicosapentanoic acid 
(EpA) and docosahexanoic acid (DhA), decrease the risk of coronary artery disease, stroke, 
and other diseases associated with an inflammatory response, such as Crohn’s disease.  More 
recently, ω-3 fatty acids have been shown to inhibit tumor growth and decrease tumor cell 
motility.  While ω-3 fatty acids are often associated with health benefits, ω-6 fatty acids have 
been implicated in a number of disease processes.  The ω-6 PUFA arachidonic acid (ArA) 
has been shown to increase cell motility and survival through inactivation of the tumor 
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suppressor PTEN [128], while another group has shown that ArA directly activates PI3K and 
up-regulates numerous inflammatory genes [129].  Because ArA is an essential fatty acid, it 
is required for normal cell homeostasis, suggesting some ArA is critical, but excess ArA can 
be problematic.   
Several studies suggest the ω-3 PUFA to ω-6 PUFA ratio is what drives cancer cell 
biology.  In prostate cancer, cells with a lower ω-3 to ω-6 ratio had increased cell survival 
and motility.  It is important to note diets in the United States typically consist of elevated 
levels ω-6, compared to a Mediterranean or Asian diet.  Numerous studies have investigated 
PPAR-γ activation by dietary fatty acids.  ArA has been implicated as a regulator of PPAR-γ 
activity as well, down regulating transcription of a PPAR-γ target gene GLUT4 [130].  One 
group showed a differential effect of ω-3 versus ω-6 fatty acids on PPAR-γ transcriptional 
activity [131], with ω-3 fatty acids down regulating PPAR-γ activity.  
Increased long-chain ω-6 fatty acids in adipose tissue of the breast have been shown 
to correlate with development of breast cancer [13,132].  In vivo, increasing ω-6 fatty acid in 
mice with prostate cancer xenografts results in increased tumor growth and final tumor 
volumes [14].  Tumors in mice fed increased ω-3 fatty acids had increased apoptosis and 
decreased proliferation, suggesting a protective role of ω-3 fatty acids in tumor progression 
[14].  In breast cancer cells, gene expression is differentially regulated by ω-3 and ω-6 fatty 
acids [15].  A number of animal studies also suggest a protective role for ω-3 fatty acids in 
breast cancer progression [133].  Recently, a study showed ω-3 fatty acids inhibits HER-
2/neu-induced breast cancer in transgenic mice [16], independent of PPAR-γ activity.  Taken 
together, these studies begin to explain the role of diet and obesity in cancer risk and 
development.         
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The importance of the tumor microenvironment must not be overlooked in cancer 
research.  In recent years, evidence has increasingly shown the relationship between tumor 
cells and the surrounding stromal cells.  In prostate cancer, there are reports of cross-talk 
between bone and metastasized prostate carcinoma cells, promoting growth and survival of 
metastatic lesions [134].  Adipocytes have been shown to promote tumor growth by secretion 
and processing of collagen IV, which activates AKT signaling pathway in breast epithelial 
cells [135].  Using proteomic analysis of adipocyte cells and interstitial fluid of fat tissue 
from the breast, another study identified proteins involved in metabolism, apoptosis and 
immune response [136].  These studies suggest a link between adipocytes in the breast tissue 
and support of tumor development and growth.   
In terms of the role of PPAR-γ in cancer-stromal cell interactions, the literature is 
both sparse and contradictory.  One in vitro study shows inhibition of adhesion between 
multiple myeloma and bone marrow stromal cells, through reduced activity of both NF-κB 
and C/EBPβ by PPAR-γ agonists [19], reducing growth and metastasis of multiple myeloma.  
Another in vitro study showed stromal cell expression of prostaglandin D synthase derived 
products suppressed prostate tumor growth and that this was mediated through PPAR-γ 
activation in the tumor cells [137].  Most in vivo characterization of PPAR-γ in tumors has 
been done through immunohistochemical analysis, which does not show activity of PPAR-γ, 
merely expression.  There are a number of citations showing PPAR-γ protein expression in 
tumor samples [117,119,138--140], though there is no definitive explanation for its presence.  
One study showed expression of PPAR-γ in pancreatic cancer is correlated with shorter 
patient survival [140], while expression of PPAR-γ in colon adenocarcinoma samples 
corresponded to increased expression of cell-cycle molecules [119].  These results suggest 
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PPAR-γ activation may be used to induce expression of cell-cycle machinery.  While these 
studies reveal the presence of PPAR-γ in tumor cells, without evidence suggesting PPAR-γ 
activity, one cannot fully understand the role of PPAR-γ in tumor cell biology in vivo.          
     
Summary 
 While there is a substantial amount of data on PPAR-γ pertaining to its role in normal 
cell function and diabetes, there is no solid understanding of its function in cancer cell lines 
or tumor samples.  The in vitro data supports a role for PPAR-γ in differentiation of tumor 
cells [28] as well as induction of apoptosis [141--143], though there are no strong in vivo data 
to support the in vitro results.  What is known is that obesity exhibits a number of hallmarks 
for altered PPAR-γ function, including dysregulation of adipokine secretion.  In this review, 
we have presented support for our hypothesized mechanism of increased breast cancer risk in 
obese individuals.  With elevated levels of PAI-1 in obese women, the potential is there for 
increased proliferation, decreased apoptosis and increased cellular migration, all contributing 
to tumor development and metastasis in the breast (Figure 2.1).  The close proximity to a 
large pool of adipose tissue in the microenvironment could predispose obese women to 
developing breast cancer.    
The potential to use PPAR-γ agonists as chemotherapeutic agents in breast cancer is a 
very viable option.  It is possible that inducing PPAR-γ activity systemically in the obese 
individual could alter PAI-1 expression, resulting in a less pathogenic phenotype in the breast 
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Figure 2.1.  The potential role of PPAR-γ, fatty acids, adipose tissue, and the 
plasminogen activator system in breast cancer. 
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tissue.  Less toxic PPAR-γ agonists, such as pioglitazone or rosiglitazone, both FDA 
approved and commercially available to treatment of diabetes, may prove to be useful 
chemotherapeutic agents for breast cancer patients. 
 
 
Acknowledgements- Stipend support to J.C.C. was provided by NIEHS 5T32-ES-
07017 from the National Institute of Environmental Health Sciences, and the Sequoyah 
Fellowship from the Graduate School, UNC Chapel Hill.  This research was supported in part 
by Research Grants (BCTR0503475 and BCTR45206) from the Susan G. Komen Breast 
Cancer Foundation to F.C.C. 
 
 
 
 
 
 
  
  
 
 
Chapter III 
 
 
Characterization of the Plasminogen Activator System  
in the MCF-10A Family of Cell Lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
30 
 
Abstract 
Plasminogen activator type-1 (PAI-1) is a member of the serine protease inhibitor 
(serpin) family of proteins.  A key physiological role of PAI-1 is to inhibit the serine protease 
urokinase type-plasminogen activator (uPA).  In addition to mediating breakdown of the 
extracellular matrix through plasminogen activation, uPA is responsible for cellular motility 
through signaling cytoskeletal rearrangement when bound to its cell-surface urokinase 
receptor (uPAR).  PAI-1 binds to the active site of uPA, preventing activation of 
plasminogen.  The goal of this study was to characterize the plasminogen activator (PA) 
system in the MCF-10A family of cell lines.  The MCF-10A cells are a normal breast 
epithelial cell line, which was used to derive a family of breast epithelial cells which 
represent normal (MCF-10A), preneoplastic (MCF-10AneoT and MCF-10AT) and 
neoplastic (MCF-10CA1) cell lines.  Immunoblot analysis of conditioned media from these 
cell lines was used to evaluate PAI-1 and uPA protein levels.  PAI-1 levels were highest in 
the normal MCF-10A, which expressed very little uPA.  The highly tumorigenic MCF-
10CA1 cells expressed significantly higher levels of uPA protein compared to the MCF-10A, 
with a noticeable decrease in PAI-1 protein levels.  Cell motility was measured using the 
modified-Boyden chamber model.    MCF-10CA1 cell motility was increased compared to 
the normal MCF-10A cells.  Interestingly, when uPA activity was inhibited by amiloride, 
MCF-10CA1 cell motility decreased to that of the MCF-10A cells.  Furthermore, 
phosphorylated-AKT levels were found to be elevated in MCF-10CA1 cells, which partially 
explains the imbalance between uPA and PAI-1 production in these cell lines.  These 
findings imply the PA system is dysregulated in MCF-10CA1 cells compared to the more 
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normal MCF-10A cells, resulting in a more aggressive phenotype with regards to tumor 
migration and invasion.   
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Introduction 
The plasminogen activator (PA) system plays a key role in tumor cell migration.  The 
PA system is composed of the urokinase-type (uPA) and tissue-type (tPA) plasminogen 
activators, the serine protease inhibitor (serpin) plasminogen activator inhibitor type-1 (PAI-
1), and the cell surface receptor for uPA (uPAR).  In normal physiology, the PA system, 
through tPA activity, functions to maintain normal hemostasis through clot fibrinolysis.  In 
the pericellular environment, uPA is the main source of plasminogen activation, resulting in 
degradation of extracellular membrane (ECM) proteins.  In both situations, PAI-1 binds the 
active site of the plasminogen activators and inhibits plasmin generation [144,145].  In breast 
cancer, elevated levels of uPA and, paradoxically, PAI-1 are indicative of decreased patient 
survival [74].  This paradox has been studied for years and there is much evidence PAI-1 
functions outside of its role as a serine protease inhibitor.   
While the physiological role of PAI-1 is to inhibit tPA and uPA activity, recent 
research has further implicated PAI-1 activity in cell signaling, adhesion, and migration 
[61,79,146,147].  PAI-1 has been shown to inhibit apoptosis and to promote angiogenesis, 
which are two key regulators of tumor formation [148--152].  However, there are 
contradictory studies suggesting there is a concentration or context specific effect of PAI-1 to 
inhibit migration, angiogenesis and to induce apoptosis.  In nude mice, Tet-induced PAI-1 
expression resulted in decreased tumor growth, mediated through induction of apoptosis in 
endothelial cells [153].  
The MCF-10A family of cell lines was developed as a model of progressive breast 
disease [154,155].  The cell lines were generated from the normal breast epithelial cell line 
MCF-10A.  The MCF-10A cells were then transformed with oncogenic Ras, which resulted 
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in a preneoplastic line, MCF-10AT [156,157].  The malignant MCF-10CA1 cell line was 
derived from the MCF-10AT cell lines [155].  Our lab is interested in utilizing the MCF-10A 
family of cell lines, allowing us to investigate specific changes in the PA system between 
normal and malignant breast epithelial cells, especially with regard to motility and signaling 
related to the PA system.         
We previously showed that phosphatidylinositol-3 kinase (PI3K) activation increases 
uPA expression, decreases PAI-1 expression and increases migration of ovarian SKOV-3 
cells [158].  In generating the preneoplastic MCF-10AT cell lines, normal epithelial cells 
were transformed with the signaling molecule, oncogenic Ras [154].  Ras is an upstream 
mediator of PI3K.  We are interested in investigating PI3K activity in the MCF-10A cells 
lines, as PI3K activity is implicated in cell survival, proliferation, and increased cell 
migration, resulting in a malignant phenotype in epithelial cells.  Thus, it was of interest to 
determine if oncogenic-Ras transformation of MCF-10A cells affected PI3K activity with 
concomitant changes in uPA and PAI-1 expression.  
The goal of our study was to characterize the PA system in the MCF-10A family of 
cell lines.  We discovered uPA was upregulated in the preneoplastic and malignant cell lines, 
while the normal MCF-10A cells expressed very little uPA.  Using the normal cell line and 
the malignant MCF-10CA1 cells, we examined alterations in cell motility and found MCF-
10CA1 motility is greatly enhanced compared to the normal MCF-10A cells.  Blocking uPA 
activity with amiloride resulted in a reduction of MCF-10CA1 cell motility.  When we 
inhibited PI3K activity in the MCF-10CA1 cells, we found a reduction in uPA activity to a 
rate similar to that seen in untreated MCF-10A cells.  Collectively, these results suggest the 
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dysregulation in the PA system components is in part responsible for the more aggressive 
phenotype of the MCF-10CA1 cells.         
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Materials and Methods 
Cell culture 
MCF-10A, MCF-10AneoT, MCF-10AT, and MCF-10CA1 cells (obtained from Dr. 
F. Miller, Wayne State University, Detroit, MI) were cultured as previously described 
[155,157].  Briefly all cell lines were cultured in DMEM:F12 (GIBCO®, Invitrogen, 
Carlsbad, CA) containing 5% horse serum (HyClone, Logan, UT), 1% PSF (GIBCO®, 
Invitrogen, Carlsbad, CA), 20µg/ml EGF (Invitrogen, Carlsbad, CA), 50ng/ml 
hydrocortisone, 100ng/ml cholera toxin (CalBiochem, San Diego, CA) and 10µg/ml insulin 
(GIBCO®, Invitrogen, Carlsbad, CA).  Cells were grown in a humidified atmosphere of 5% 
CO2 at 37˚C.  Serum-starvation was done for 24 hours in media not containing horse serum. 
 
Semi-quantitative PCR 
 RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen, Valencia, 
CA) according to manufacturer’s protocol.  Two µg total RNA was reverse transcribed using 
Moloney Murine Leukemia Viruse reverse transcriptase (M-MLV, Invitrogen, Carlsbad, CA) 
following the manufacturer’s protocol.  cDNA was amplified over 30 cycles [denaturation- 
94˚C for 30 s, annealing- at primer specific temperatures (in parentheses following each 
primer set) for 30 s, and elongation- 72˚C for 30 s].  Primer sequences were: PAI-1 (61˚C) 
forward- 5’AAT CAG ACG GCA GCA CTG TC3’, reverse- 5’ CTG AAC ATG TCG GTC 
ATT CC 3’; uPA (55˚C) forward- 5’ GGC AGC AAT GAA CTT CAT CAA GTT CC 3’, 
reverse- 5’ TAT TTC ACA GTG CTG CCC TCC G 3’; uPAR (60˚C) forward- 5’ ACA 
GGA GCT GCC CTC GCG AC 3’, reverse- 5’ GAG GGG GAT TTC AGG TTA GG 3’; β-
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actin (55˚C) forward- 5’ ATC ATG TTT GAG ACC TTC AA 3’, reverse 5’ CAT CTC TTG 
CTC GAA GTC CA 3’.    
Immunoblot analysis 
Cells were grown to confluence in a 6-well plate, and were then washed in ice-cold 
PBS after 24 hour serum starvation.  Cell lysates were collected in ice cold buffer containing 
50mM Tris, 0.1% sodium dodecyl sulfate (SDS), 150mM NaCl, 1mM PMSF, 1mM EDTA, 
1% Triton X-100, 1% sodium deoxycholate, 5µg/ml aprotinin, and 5µg/ml leupeptin.  During 
lysis, cells were kept on ice.  Lysates were centrifuged to remove insoluble plasma 
membrane, and protein concentration was calculated using the Protein DC assay (BioRad, 
Hercules, CA).  Conditioned media from treated cells was collected and concentrated using a 
centrifugal filter device (Amicon Ultracel 30k, Millipore, Billerica, MA).  Protein 
concentration was determined using BioRad Protein DC assay (BioRad, Hercules, CA).  
Proteins were separated by SDS-PAGE in 10% polyacrylamide and electrotransfered to 
PVDF membrane.  Phosphate buffered saline/0.1% Tween-20 (PBS/Tween) buffer was used 
in all steps of immunoblot analysis.  Each step was preceded by three 9-minute washes at 
room temperature.  Non-specific binding was blocked by 5% nonfat dry milk for 30 minutes 
at room temperature.  Membrane was incubated at 4˚C overnight with primary antibody 
diluted 1:1000 (unless otherwise noted) in 1% nonfat dry milk.  Membrane was then 
incubated for 1 hour at room temperature to horseradish peroxidase conjugated secondary 
antibody diluted 1:5000 in 1% nonfat dry milk.  Membrane was exposed to luminal substrate 
for 1 minute, covered in plastic wrap then exposed to X-ray film.  Primary antibodies: goat 
anti-uPAR (sc-9793, Santa Cruz Biotech, Santa Cruz, CA), rabbit anti-ERK2 (Santa Cruz 
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Biotech, Santa Cruz, CA), rabbit anti-PAI-1 (1:2000 dilution) (ASHPAI, Molecular 
Innovations, Novi, MI) and rabbit anti-uPA (#389, American Diagnostica, Stamford, CT). 
 
Motility assay 
Cell motility was determined using a 48-well chemotaxis chamber (Neuro Probe, 
Gaithersburg, MD), as described previously [159].  Briefly, cells were serum starved for 24 
hours prior to experiment.  Treatment was added to the cells for 24 hours.  Assay was 
performed as previously described.  Briefly, lower wells on chamber contained DMEM:F12 
plus 1mg/ml fatty-acid free bovine serum albumin (BSA, Sigma, St. Louis, MO) with or 
without 5ng/ml EGF (Invitrogen, Carlsbad, CA).  Cells (1 X 105) were plated in upper wells 
in DMEM:F12 containing 1mg/ml fatty-acid free BSA, above a collagen IV coated (Sigma, 
St. Louis, MO) 10µm porated polycarbonate membrane (Neuro Probe, Gaithersburg, MD).  
Chambers were incubated at 37˚C for 6 hours in a humidified atmosphere.  Cells were fixed 
and stained with Diff-Quick Stain Kit (Dade-Behring, Newark, DE).  Cells which migrated to 
the undersurface of the membrane were examined microscopically at 200X magnification.  
Cells in 4 fields were counted, numbers represent average number of cells/well + SD.  All 
conditions were done in triplicate. 
 
Indirect cell-surface associated uPA activity assay 
MCF-10A and MCF-10CA1 cells (1 X 104) were plated in a 96-well plate.  Following 24 
hour serum starvation, cells were then treated with 10mM LY294002 or control (DMSO) for 
24 hours at 37˚C.  After treatment, cells were washed with PBS.  Plasminogen (3 µg, in 54 
µl) (Chromogenix, Milan, Italy) and buffer containing 100 mM Tris and 0.5% Triton X-100 
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(pH 8.8) (qs to 100 ml) were added to cells and incubated at room temperature for 30 
minutes.  Following incubation, 5 µl supernatant was removed and added to another 96-well 
plate containing 74.8 µl buffer (100 mM Tris, pH 8.8 with 0.5% Triton X-100) and 5 µl 
amiloride (6 mM, from 100 mM DMSO stock) to inhibit any residual uPA activity.  Plasmin 
chromogenic substrate (S-2251, Chromogenix, Milan, Italy) was then added to the well (total 
volume = 100 µl) and hydrolyzed by plasmin generated by plasminogen cleaved by uPA on 
the cell surface.  Kinetics were read at 405nm for 90 minutes.  A plasmin standard curve was 
prepared using a serial dilution of purified human plasmin (Chromogenix, Milan, Italy).   
 
Wound-induced migration 
 Cells were plated in a 12-well plate at 1.0 X 105 cells per well and grown to 
confluence.  Following overnight serum starvation, cell monolayers were scratched with the 
tip of a sterile yellow pipet tip.  Cell debris was removed and cells were washed with PBS.  
LY294002 treated serum-free media was added to the wounded monolayer.  Migration of 
cells was monitored at 0, 6, and 12 hours using a Kodak MDS290 camera and software.  
Wound closure was quantified by measuring distance as pixels between each leading edge of 
the wound (10 lines/wound) at each time point using the measuring tool in Adobe 
Photoshop®, with a grid superimposed on image to guide measurements.   
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Results 
Expression of PA system components in MCF-10A family of cell lines 
 The MCF-10A family of cell lines (MCF-10A, MCF-10AneoT, MCF-10AT, and 
MCF-10CA1) was examined for mRNA and protein expression of the components of the PA 
system (uPAR, uPA, and PAI-1).  Using semiquantitative PCR to evaluate PAI-1, uPA, 
uPAR, we did not see any difference in expression between the four cell lines (Figure 3.1A).  
MDA-MB-231 cells were used as a positive control cell line, as they have previously been 
shown to express all three components of the PA system [160].  Cell lysates collected from 
the four cell lines were evaluated by immunoblot analysis for uPAR expression.  No 
significant change in uPAR expression was found among the cell lines (Figure 3.1B).  As 
PPAR-γ pertains to research presented in other chapters, we examined PPAR-γ expression 
and found all cells in our system expressed high levels of the protein (Figure 3.1B).  Using 
conditioned media to examine the expression of the secreted proteins uPA and PAI-1, there 
were noticeable differences in expression patterns of the two proteins.  PAI-1 expression was 
highest in the normal MCF-10A cells, with decreasing expression correlating with the 
previously described in vivo invasiveness of cells, with the highly tumorigenic MCF-10CA1 
cell line expressing the lowest levels of PAI-1(Figure 3.1C).  uPA protein levels were 
significantly higher in the MCF-10CA1 cells compared to the MCF-10AneoT, MCF-10AT, 
and MCF-10A cells (Figure 3.1C).  Cell-surface uPA activity levels were consistent with 
immunoblot analysis, with lowest levels in the normal and preneoplastic cell lines, while 
MCF-10CA1 cells have significantly higher activity (Figure 3.2).     
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Figure 3.1.  Expression of various components of the PA system in the MCF-10A series 
of cell lines.  A. rtPCR analysis of uPA, uPAR, and PAI-1 in the MCF-10A series of cell lines.  For gene 
specific primer sequences and reaction set-up, see “Materials and Methods”.  β-actin was amplified to ensure 
equal loading and successful amplification.  B.  Protein expression of uPAR in cell lysates, 10µg total protein 
loaded per cell line.  Membrane was probed for ERK-2 to ensure equal loading of protein.  C.  Protein 
expression of PAI-1 and uPA in conditioned media from cells.  10µg total protein loaded per cell line.     
 
 
 
A. 
B. C. 
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Figure 3.2.  Plasmin generation is significantly higher in MCF-10CA1 cells compared to 
MCF-10A cells.  Cells were plated at 1.0 X 104 cells per well.  At confluence, cells were serum-starved for 
24-hours.  Following serum starvation, cells were washed in PBS.  Plasminogen was incubated on the cell 
surface for 30 minutes, and then supernatant was transferred to new 96-well plate containing amiloride to block 
remaining uPA activity.  Plasmin chromogenic substrate was added to supernatant and kinetics of substrate 
cleavage was monitored at Ab 405 nm for 1.5-hours at 37˚ C.  Concentration of plasmin generated was 
determined from plasmin standard curve.  Experiments were done in triplicate, and values represent average 
[plasmin] generated/experiment + SD (n=4).    
 
 
 
 
 
 
 
 
 
 
MCF-10A MCF-10CA1
0.0
0.2
0.4
0.6
0.8
1.0
[P
la
sm
in
] n
g/
m
l
  
42 
 
MCF-10CA1 cells are more motile in vitro than MCF-10A cells 
Given the significant alteration in expression of PAI-1 and uPA in the MCF-10CA1 
cells compared to the MCF-10A cells, we next investigated the in vitro motility of the cells, 
using the modified-Boyden chamber model. MCF-10CA1 cells (133.2 cells/well) were more 
motile than MCF-10As (82.89 cells/well) when chemotaxing to EGF (Figure 3.3).  Random 
migration of MCF-10CA1 cells was also elevated over MCF-10A cells (79.92 cells/well 
compared to 14.08 cells/well, respectively) (Figure 3.3).  While the MCF-10A cell 
chemotaxis increased 5.8-fold to EGF compared to migration to BSA alone, the increase in 
MCF-10CA1 cell motility was less dramatic (1.67-fold increase). This is likely due to the 
fact that these cells start out at a very motile baseline, while significantly fewer MCF-10A 
cells randomly migrate, resulting in a lower baseline. 
 
Blocking uPA activity attenuates MCF-10CA1 cell motility 
  Amiloride, a selective inhibitor of uPA and sodium uptake inhibitor, was added to 
MCF-10CA1 cells to determine if blocking uPA activity would decrease cell motility.  
Amiloride (200 µM) reduced cell surface uPA activity in MCF-10CA1 cells by 50 percent 
(Figure 3.4). Modified-Boyden chamber assays were then utilized to compare MCF-10A cell 
motility to MCF-10CA1 cell motility following amiloride treatment.  By blocking uPA 
activity, MCF-10CA1 cell motility was reduced essentially to that of the MCF-10A cells 
(Figure 3.4), suggesting uPA activity is partly responsible for the increased chemotaxis in 
MCF-10CA1 cells. 
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Figure 3.3.  MCF-10CA1 cells are more motile than MCF-10A cells.  A. Cells were serum-starved 
overnight, then plated in the upper chamber of the modified-Boyden chamber in DMEM:F12 + 1mg/ml fatty 
acid free BSA.  Photomicrographs of cells fixed and stained on 10µm porated, collagen IV coated PVDF 
membrane.  B.  Graph of average number of cells counted on bottom of membrane following 6-hour incubation 
at 37˚C.  Four fields per well were counted, three wells per condition.  Graph represents the average of 4 
separate experiments + SD.  ** p< 0.01. 
** 
** 
A. MCF-10A 
5ng/ml EGF 
MCF-10CA F-10  
0ng/ml EGF 
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Figure 3.4.  Blocking uPA activity reduces MCF-10CA1 cell motility.  A.  Amiloride treatment 
decreases cell-associated uPA activity.  Following 24-hour treatment, MCF-10CA1 cells treated with amiloride 
(200µM) were able to generated less plasmin.  Medium was removed from cells, washed in 1X PBS and 
plasminogen was then added.  After 30-minutes at room temperature, cell supernatant was transferred to wells 
containing plasmin chromogenic substrate (S-2251, Chromogenix).  Kinetics were read at 405nm for 1.5-hours 
at 37˚C.  Values represent average Vmax at Ab 405nm, normalized to no treatment control, each condition done 
in triplicate.  n=3, *p<0.05.  B.  After a 24-hour treatment with amiloride (200µM) or DMSO control, cells were 
plated on 10µm porated collagen IV coated membranes.  After a 6-hour incubation, cells on the bottom of the 
membrane were fixed and stained, and the membrane was sandwiched between two glass slides.  Cells were 
counted in 4 fields per well, in triplicate for each condition.  Values represented as average number of cells per 
well + SD, n=3.  *p<0.05.  Amiloride treatment significantly reduced the number of MCF-10CA1 cells that 
migrated to both BSA and EGF.   
MCF-10A             +                           + 
MCF-10CA1                    +       +                 +        + 
0ng/ml EGF         +        +       +   
5ng/ml EGF                                         +       +        + 
200µM Amiloride                     +                           + 
* 
* 
A. 
B. 
* 
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Phospho-Akt levels are elevated in MCF-10CA1 cells 
PI3K has been implicated in tumor cell survival, cell motility and cell proliferation.    
Since the MCF-10CA1 cell line was derived from the H-ras transformed MCF-10AT cell 
line, increased PI3K activity, as measured by phosphorylated-Akt levels, should be evident  
 (Figure 3.5).  Interestingly, phospho-Akt levels increased as the aggressiveness of the cells 
increased, being lowest in MCF-10A and highest in MCF-10CA1 (Figure 3.5).  Previously, 
we showed that activation of PI3K, measured by phospho-Akt levels, results in increased 
uPA levels and decreased PAI-1 levels [158].  Therefore, we next investigated the effects of 
inhibiting PI3K activity in the MCF-10CA1 cells.  When MCF-10CA1 cells were treated 
with the PI3K inhibitor LY249920, cell surface uPA activity of the MCF-10CA1 cells 
decreased significantly (Figure 3.6A).  Expression of uPA protein was also reduced by 
LY294002 treatment (Figure 3.6A).  Inhibition of PI3K with LY294002 in the modified-
Boyden chamber model did not reduce MCF-10CA1 chemotaxis to EGF, possibly because 
PI3K is also activated by EGF; thus the chemoattractant is overriding the effect of prior 
LY294002 treatment.  Alternatively, we were able to use a wound-induced migration model 
to study the effect of LY294002 on uPA dependent migration.  In the wound-induced 
migration model, inhibition of PI3K/Akt by 10µM LY294002 reduced cell migration 22.03% 
at 12 hours compared to the DMSO vehicle control treatment (Figure 3.6B).  At the 24-hour 
timepoint, the control MCF-10CA1 cells were 99.91% closed, compared to the 10µM 
LY294002 treated which was only 63.66% closed, a difference of 36.58% (Figure 3.6B).      
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Figure 3.5.  MCF-10CA1 cells express more phospho-Akt than MCF-10A cells, but LY294002 
reduces phospho-Akt expression in MCF-10CA1 cells.  A.  MCF-10A cell lines were serum starved for 
24 hours.  Whole cell lysates were then harvested in RIPA buffer.  Based on protein concentration as 
determined using a colorimetric assay, 10 µg total protein was separated on a 10% polyacrylamide gel, 
transferred to PVDF membrane, and for active (phospho-Ser473) Akt (Cell Signaling, Danvers, MA), total Akt 
(Cell Signaling, Danvers, MA), and alpha-tubulin (Santa Cruz Biotechnologies, CA) as a protein loading 
control.  B.  MCF-10CA1 cells were treated with LY294002 (0 µM, 10 µM, and 20 µM) for 24 hours, then cells 
were lysed in RIPA buffer.  10 µg total protein was separated per condition on 10% SDS-PAGE, transferred to 
membrane and probed for active (phospho-Ser473) Akt (#9721, Cell Signaling, Danvers, MA) and total Akt 
(#9722, Cell Signaling, Danvers, MA).   
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Figure 3.6.  LY294002 treatment decreases cell-surface uPA activity in MCF-10CA1 cells.  A.  
PI3K inhibitor LY294002 reduces expression of uPA protein and cell-surface associated uPA activity.  
LY294002 (10 µM and 20µM) treatment for 24 hours reduces plasmin generation in MCF-10CA1 cells.  Values 
represent average Vmax (Ab405nm), normalized to control, experiment done in triplicate, n=3.  Inset.  
Immunoblot for uPA protein in conditioned media following LY294002 treatment.  LY294002 treatment 
(10µM and 20µM) reduces expression of uPA protein.  10  µg total protein loaded to 10% SDS polyacrylamide 
gel, then transferred to a PVDF membrane.  Rabbit anti-human uPA antibody (#389, American Diagnostica, 
CT) was used to probe the membrane.  HRP-conjugated secondary antibody (Sigma, MO) was detected by 
enhance chemiluminescence (Pierce, IL).  B.  MCF-10CA1 cells were plated at 1.0 X 105 cells per well in a 12-
well plates and grown to confluency.  Following serum starvation, cells were scratched with a yellow pipet tip 
and cells were washed in PBS.  Treatment was added (0µM and 10 µM LY294002) in serum-free media and 
wound closure was monitored and photographed at time points (0, 6, 12, and 24 hours).  Wound remaining was 
measured using Photoshop® measure tool.  Values represent average distance between two edges of wound, 
normalized to 0 hour measurements, with 10 measures per well, each condition in triplicate. Values represent 
average + SD, n=2. **= p<0.01          
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Discussion 
 The MCF-10A family of cell lines was previously generated and characterized in 
nude mice [155,157].  The usefulness of the cell lines stems from the fact that they were 
generated from the normal epithelial cell line, the MCF-10As.  Our interest was to compare 
and contrast differences in the PA system components and potential differences in motility in 
vitro.  As these cell lines were new to our laboratory, we first began by characterizing the PA 
system in all four cell lines.  We studied PAI-1, uPA and uPAR mRNA and protein levels.  
Interestingly, PAI-1 protein levels were noticeably lower in MCF-10CA1 cells compared to 
MCF-10A cells, while uPA protein levels were significantly higher.  Thus, the ability to 
generate plasmin in MCF-10CA1 cells was much higher compared to MCF-10A cells as 
well, supporting the immunoblot analysis.  Our results support in vivo invasion data that 
initially characterized these cell lines [155,157].  Therefore, these results collectively support 
the notion that the increase in uPA to PAI-1 ratio in the MCF-10CA1 cells is correlated with 
increased invasiveness.   
The MCF-10A cells are widely used in studies as a normal breast epithelial cells, 
often comparing them to malignant epithelial cell lines [161--164].  Interestingly, there is 
very little in the literature comparing and contrasting MCF-10A cells with the malignant 
MCF-10CA1 cells derived from these normal cells.  There has been little reported about the 
migratory phenotype of these cells in vitro, so one of our goals was to characterize the 
motility of these cells in culture, using the modified-Boyden chamber model.  The MCF-10A 
cells had a very low baseline of chemotaxis, compared to the MCF-10CA1 cell baseline.  
These results are not surprising, given the in vivo data [154].   
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uPA has long been known as a key mediator in tumor cell biology.  In 1990, Botteri, 
et al. demonstrated uPA participates in cytoskeletal rearrangement in tumor cells [165].  uPA 
was also shown to induce epidermal tumor cell proliferation [166].  uPA bound to uPAR 
promotes migration and invasion of a number of cancer cell types [55].  Given the 
importance of uPA activity in tumor cell migration [167--169], we next determined the 
effects of uPA inhibition on MCF-10CA1 cell migration.  Amiloride has been shown to 
inhibit uPA expression and activity [170,171].  By blocking uPA activity with amiloride, we 
reduced MCF-10CA1 cell motility down to a level comparable to MCF-10A cell motility 
baseline.  These results suggest the elevation of uPA in the MCF-10CA1 cells are partly 
responsible for the phenotype seen in these cells.     
Multiple studies have shown uPA and more recently PAI-1 expression is regulated by 
intracellular signaling, specifically the phosphatidylinositol-3 kinase pathway.  Shukla, et al. 
found activation of the PI3K/Akt pathway increases invasion in prostate cancer cells, as a 
result of PI3K/Akt up-regulation of uPA expression [172].  Whitley, et al. reported a similar 
effect of up-regulated uPA expression linked to a negative effect of PAI-1 expression in 
SKOV-3 ovarian cancer cells [158].   PI3K/Akt signaling has been implicated in tumor cell 
survival, proliferation, and migration [174--177].  Since the literature suggests uPA 
expression is linked to PI3K/Akt activity and because the MCF-10A cells were transformed 
with oncogenic-Ras, an upstream activator of PI3K [178], we hypothesized the MCF-10CA1 
cells would have increased PI3K/Akt phosphorylation.  We found a significant increase in 
Akt phosphorylation in the MCF-10CA1 cells compared to normal MCF-10A cells.  These 
data suggest increasing PI3K activity through transformation with the upstream modulator 
oncogenic-Ras results in an increase of uPA expression and activity, balanced by the 
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reduction in PAI-1 expression.  By altering the balance of PAI-1:uPA ratio in favor of uPA, 
the MCF-10CA1 cells become more aggressive, as seen by cellular motility in vitro and in 
vivo.       
In characterizing MCF-10A to MCF-10CA1 cell lines, we have described an in vitro 
alteration in the PA system that is consistent with both in vitro migratory phenotypes of these 
cell lines and in vivo invasion originally described.  Therefore, these cells provide an 
excellent backbone to pursue further investigation and manipulation of the PA system, as it 
relates to malignant breast disease.      
 
  
 
Chapter IV 
 
Peroxisome Proliferator-Activated Receptor-gamma Ligands Alter MCF-10A Family Cell 
Motility Through Modulation of the Plasminogen Activator System 
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Abstract 
PPAR-γ has been shown to be the master regulator of adipogenesis.  As a member of 
the nuclear-receptor superfamily, PPAR-γ is a ligand activated transcription factor.  A 
number of PPAR-γ ligands have been identified, including the thiazolidinedione (TZD) 
antidiabetic drugs, 15-deoxy-∆12,14-prostaglandin J2 (15d-PGJ2) and dietary fatty acids.  
PPAR-γ activation has been found to regulate plasminogen activator inhibitor-1 (PAI-1) 
expression in adipocytes and endothelial cells.  Additionally, PPAR-γ activation has been 
shown to induce apoptosis and terminal differentiation in a number of tumorigenic cell lines.  
We investigated how various PPAR-γ ligands regulated the plasminogen activator system in 
breast epithelial cells to alter breast cancer cell motility; thus, we compared normal MCF-
10A and malignant MCF-10CA1 cell lines. MCF-10A and MCF-10CA1 cells treated with 
the TZD ciglitazone, and saw a significant reduction in chemotaxis.  Interestingly, that effect 
was not reversed with pretreatment of a PPAR-γ specific antagonist.  Immunoblot analysis of 
conditioned media showed ciglitazone treatment decreased PAI-1 expression in both cell 
lines; this effect was also unaltered by PPAR-γ antagonism.  The results suggest ciglitazone 
acts independently of PPAR-γ to negatively regulate PAI-1, resulting in a decrease of normal 
and malignant breast epithelial cell migration.  By contrast, MCF-10A treatment with the ω-6 
fatty acid arachidonic acid (ArA) increased both cell migration and cell surface uPA activity.  
Interestingly, pretreatment with a PPAR-γ antagonist reversed these effects, suggesting ArA 
mediates these effects on cell motility and uPA activity through PPAR-γ activation.  Taken 
together, the data suggest known PPAR-γ ligands have a differential effect on cell migration 
and the PA system, resulting from PPAR-γ dependent and PPAR-γ independent effects, on 
both normal and malignant epithelial cells. 
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Introduction 
Breast cancer is the leading form of cancers diagnosed in women, with an estimated 
170,000 new cases diagnosed each year.  A function of any tumor cell that allows for 
propogation of diseased cells is the ability for that tumor cell to invade the surrounding 
tissue, eventually leading to intravasation into the surrounding lymphatics and vasculature 
and moving to distant sites of metastasis.  One family of proteins involved in this 
pathological process is the plasminogen activator (PA) system.  The PA system includes the 
urokinase-type plasminogen activator (uPA), which activates plasminogen to plasmin, 
allowing for cleavage of extracellular matrix (ECM) proteins and activation of matrix 
metalloproteinases, which futher degrade the ECM.  uPA is most active when bound to its 
cell surface urokinase receptor, uPAR.  In addition to the role of the uPA/uPAR complex in 
degradation of the ECM, this complex plays a role in cell adhesion.  uPAR is able to engage 
cell surface integrins, allowing for attachment of cells expressing the uPA/uPAR complex to 
other surrounding cells.   
Another key component of the PA system is plasminogen activator inhibitor type-1 
(PAI-1), the physiological inhibitor of uPA activity.  PAI-1 binds uPA bound to the cell 
surface, forming a PAI-1/uPA/uPAR complex that is then recognized by the scavenger 
protein low density lipoprotein receptor-related protein (LRP), which internalizes the tertiary 
complex [179,180].  PAI-1 and uPA are then degraded, and uPAR is recycled to the cell 
surface.  Paradoxically, elevated levels of PAI-1 are associated with decreased patient 
survival [74].  The mechanism is not fully understood, though there are several reports 
suggesting PAI-1 plays a role in cell motility and inhibition of apoptosis [80,161].  Webb, et 
al. demonstrated PAI-1 mediates mitogen-activate protein kinase signaling following 
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formation of a complex with uPA [181].  Excess PAI-1 has been shown to increase cell 
motility through binding uPA/uPAR complex and allowing the cell to break adhesions with 
integrins, resulting in detachment of cells from the ECM [146].  Another study shows PAI-1 
increases filapodia formation and migration in ovarian cancer cells [80].  We found that 
expression of PAI-1 enhanced MDA-MB-435 cell directed migration to ECM products 
[79,182].  Addition of stable PAI-1 inhibited apoptosis in various tumor cell lines [161].  In 
endothelial cells, PAI-1 has been shown to inhibit FasL-mediated apoptosis [150].  
Peroxisome proliferator-activated receptor-gamma (PPAR-γ) is a transcription factor 
that is considered the master regulator of adipogenesis [18].  However, PPAR-γ has been 
found in numerous cell lines, including endothelial cells [183,184], normal and malignant 
prostate epithelium [30,46], and normal and malignant breast epithelium [28].  While the 
function of PPAR-γ in these cells in not well understood, there are a number of studies 
suggesting PPAR-γ activation has a role in promoting terminal differentiation [185,186], 
inducing apoptosis and inhibiting cell proliferation [187].  PPAR-γ is a ligand-activated 
nuclear transcription factor, and the target of the thiazolidinedione (TZD) class of insulin 
sensitizing drugs [18,26].  Drugs in this family bind PPAR-γ, resulting in the activation of the 
PPAR-γ/retinoid X receptor (RXR) heterodimer.  PPAR-γ then binds the PPAR response 
element (PPRE) in the promoter of target genes, recruits co-activators, and then the gene is 
transcribed.  In addition to TZD drugs, PPAR-γ has been shown to be activated by the 
naturally occurring 15-deoxy-∆12,14-prostaglandin J2 (15d-PGJ2) [22].  Although 15d-PGJ2 
is a potent agonist for PPAR-γ in vitro, there is data suggesting 15d-PGJ2 is not found at a 
high enough concentration in circulation to act as an in vivo ligand for PPAR-γ [188].   
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In addition to the TZD class of drugs and 15d-PGJ2, PPAR-γ has also been shown to 
be activated by a number of dietary fatty acids, specifically omega-3 (ω-3) and omega-6 (ω-
6) fatty acids.  A diet high in fat is associated with the development of a number of diseases, 
including cardiovascular disease, type 2 diabetes mellitus, and a variety of cancers.  Dietary 
fat intake has been linked to prostate cancer risk [189], colon cancer [190--192], and breast 
cancer [90].  Thoennes, et al, showed differential transcriptional activity by PPAR-γ 
following treatment of MCF-7 cells with ω-3 and ω-6 fatty acids [131].  Treatment with ω-3 
fatty acids inhibited levels of PPAR-γ activation, while ω-6 fatty acids increase PPAR-γ 
activity over control [131].     
The goal of this study was to investigate the effect of various PPAR-γ ligands on 
breast cancer cell motility.  We also examined the effects of ciglitazone on PAI-1 and uPA 
expression in MCF-10A and MCF-10CA1 cells.  We found that ciglitazone decreased cell 
motility, independent of PPAR-γ.  PAI-1 levels were lower following ciglitazone treatment.  
Pretreatment with a PPAR-γ antagonist did not reverse this effect.  Using the MCF-10A 
normal breast epithelial cells, we studied the effects of the ω-6 fatty acid arachidonic acid 
(ArA) and the ω-3 fatty acid docosahexanoic acid (DhA) on cell motility.  Treatment with 
ArA increased cell motility, while DhA had no significant effect, supporting the literature 
which says ω-6 but not ω-3 fatty acids promote cell motility.  It was determined that the 
effects seen with ArA treatment were PPAR-γ dependent.  We also saw a modulation in uPA 
cell surface activity, suggesting ArA activation of PPAR-γ may alter the PA system 
components.  The results of this study suggest ciglitazone decreases cell motility, in a PPAR-
γ independent manner, potentially though the down regulation of PAI-1 in both cell lines, 
while the fatty acid ArA promotes migration in a PPAR-γ dependent manner.                 
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Materials and Methods 
Cell culture 
MCF-10A and MCF-10CA1 cells (obtained from Dr. F. Miller, Wayne State 
University, Detroit, MI) were cultured as previously described [155,157].  Briefly, all cell 
lines were cultured in DMEM:F12 (GIBCO®, Invitrogen, Carlsbad, CA) containing 5% horse 
serum (HyClone, Logan, UT), 1% PSF (GIBCO®, Invitrogen, Carlsbad, CA), 20 µg/ml EGF 
(Invitrogen, Carlsbad, CA), 50 ng/ml hydrocortisone, 100 ng/ml cholera toxin (CalBiochem, 
San Diego, CA) and 10 µg/ml insulin (GIBCO®,Invitrogen, Carlsbad, CA).  Cells were 
grown in a humidified atmosphere of 5% CO2 at 37˚C.  Serum-starvation was done for 24-
hours in media not containing horse serum. 
 
In vitro wound healing assay   
 Cells were plated at 1.0 X 105 cells per well in a 12-well tissue culture treated plate.  
At confluence, cells were serum-starved overnight.  Cells were then scratched with the tip of 
a sterile yellow pipet tip and serum-free media containing various concentration of 15d-PGJ2 
(Calbiochem, San Diego, CA) or ciglitazone (Cayman Chemical, Ann Arbor, MI) from 
ethanol stocks were added to each well.  Migration of cells was monitored at 0, 6, and 12-
hours using a Kodak MDS290 camera and software.  Wound closure was quantified by 
measuring distance as pixels between each leading edge of the wound (10 lines/wound) at 
each time point using the measuring tool in Adobe Photoshop®, with a grid superimposed on 
image to guide measurements.   
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Modified-Boyden chamber assay 
Following serum starvation, cells were treated with ciglitazone, ArA (ArA-sodium 
salt, Sigma, St. Louis, MO), or DhA (DhA-sodium salt, Sigma, St. Louis, MO) in serum-free 
media for 24 hours.  Lower wells on chamber contained DMEM:F12 plus 1 mg/ml fatty-acid 
free bovine serum albumin (BSA, Sigma, St. Louis, MO) with or without 5 ng/ml EGF 
(Invitrogen, Carlsbad, CA).  Cells (1 X 105) were plated in upper wells in DMEM:F12 
containing 1mg/ml fatty-acid free BSA, above a collagen IV coated,10 µm porated 
membrane.  Chambers were incubated at 37˚C for 6-hours in a humidified atmosphere.  Cells 
were fixed and stained with Diff-Quick (Dade-Behring, Newark, DE).  Cells which migrated 
to the undersurface of the membrane were examined microscopically at 200X magnification.  
Each condition was done in triplicate, with 4 fields counted per well.  In experiments with 
GW9662, serum-starved cells were pretreated for 30 minutes with GW9662 (5 µM) 
(Calbiochem, San Diego, CA), then ciglitazone or fatty acid treatment was added to cells for 
24-hours. 
 
Cell viability assay 
MCF-10A and MCF-10CA1 cells were plated at 1.0 X 104 cells per well in a 96-well 
tissue culture plate.  Confluent cells were serum-starved 24 hours then treated with MCF-
10A serum-free media, preadipocyte serum free media, preadipocyte conditioned media, or 
adipocyte conditioned media.  Following incubation, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) reagent was added to cells, and incubated at 37˚C for 3-hours.  
Supernatant was removed and cells were washed in PBS.  DMSO was added to cells and 
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incubated at 37˚C for 30 minutes.  Absorbance was measured (Ab= 595nm) on a SpectraMax 
microplate reader (Molecular Devices, Sunnyvale, CA). 
  
Immunoblot analysis 
Conditioned media from treated cells was collected and concentrated with centrifugal 
concentrators (Amicon Ultracel 30k, Millipore, Billerica, MA).  Protein concentration was 
determined using BioRad Protein DC assay (BioRad, Hercules, CA).  Proteins were 
separated by SDS-PAGE in 10% polyacrylamide and electrotransfered to PVDF membrane.  
Phosphate buffered saline/0.1% Tween-20 (PBS/Tween) buffer was used in all steps of 
immunoblot analysis.  Each step was preceded by three 9-minute washes at room 
temperature.  Non-specific binding was blocked by 5% nonfat dry milk for 30 minutes at 
room temperature.  Membrane was incubated at 4˚C overnight with primary antibody diluted 
1:1000 (unless otherwise noted) in 1% nonfat dry milk.  Membrane was exposed for 1-hour 
at room temperature to horseradish peroxidase conjugated secondary antibody diluted 1:5000 
in 1% nonfat dry milk in PBS/Tween.  Membrane was exposed to luminal substrate for 1 
minute, covered in plastic wrap then exposed to X-ray film.  Primary antibodies were: rabbit 
anti-human PAI-1 (1:2000 dilution) (Molecular innovations, Novi, MI) and rabbit anti-
human uPA (#389, American Diagnostica, Stamford, CT). 
 
Indirect cell-surface associated uPA activity assay 
MCF-10A and MCF-10CA1 cells (1 X 105) were plated in a 96-well plate.  Following 
24 hour serum starvation, cells were pretreated with PPAR-γ antagonist GW9662 
(Calbiochem, San Diego, CA) or vehicle control for 30 minutes at 37˚C.  Cells were then 
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treated with various concentrations of ciglitazone (Cayman Chemicals, Ann Arbor, MI) or 
arachidonic acid (10µM, Sigma, St. Louis, MO) for 24 hours at 37˚C.  After treatment, cells 
were washed with PBS and plasminogen was added to cells and incubated at room 
temperature.  The supernatant was removed and added to another 96-well plate containing 
buffer amiloride to inhibit any residual uPA activity.  Chromogenic substrate is then added to 
the well and hydrolyzed by plasmin generated by plasminogen cleaved by uPA on the cell 
surface.  Rate of chromogenic substrate cleavage by plasmin was measured at 405nm for 90 
minutes.   
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
60 
 
Results 
PPAR-γ ligands decrease in vitro wound closure in MCF-10A cells 
 PPAR-γ is activated by a number of ligands.  Ciglitazone is a member of the TZD 
family of drugs, which act as an activator of PPAR-γ.  15d-PGJ2 is a naturally occurring 
ligand for PPAR-γ, though there are studies which show plasma concentrations of 15d-PGJ2 
are not high enough to act as PPAR-γ agonist in vivo.  Studies have shown both ciglitazone 
and 15d-PGJ2 can reduce cell migration in a number of tumor cell lines.  Using an in vitro 
wound healing model, we treated MCF-10A cells with varying concentrations of 15d-PGJ2 
and ciglitazone (Figure 4.1).  Ciglitazone decreased wound closure dose dependently (Figure 
4.1A), with 5µM ciglitazone reducing cell closure by 39% compared to no ciglitazone.  15d-
PGJ2 also decreased cell closure dose dependently, with 10µM 15d-PGJ2 reduced cell 
closure by 50% compared to no 15d-PGJ2 (Figure 4.1B).  These results show that PPAR-γ 
ligands decrease wound closure of MCF-10A cells, and they further support the literature that 
PPAR-γ activation inhibits migration of cancer cells in vitro.   
   
Ciglitazone treatment decreases chemotaxis of MCF-10A and MCF-10CA1 cells 
 Research has shown PPAR-γ ligands have several anti-tumor effects.  These ligands 
have been shown to induce apoptosis, inhibit cell proliferation and induce terminal 
differentiation in a number of cell lines.  To determine the effect of ciglitazone on directed 
cell migration in the normal MCF-10A or malignant MCF-10CA1 cell lines, cells were 
treated with varying concentrations of ciglitazone for 24 hours.  Ciglitazone decreased cell 
chemotaxis to EGF in a dose-dependent manner (Figure 4.2).  To determine if these effects  
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Figure 4.1.  PPAR-γ ligands decrease in vitro wound closure in MCF-10A cells.  A.  
Ciglitazone decreases wound closure at 12 hours.  MCF-10A cells (1 X 105) were plated in 12-well plates and 
grown to confluency.  Cells were then serum-starved overnight.  Following serum starvation, cells were 
scratched with a yellow pipet tip, cell debris was removed and cells were washed in PBS.  Scratched cells were 
treated with ciglitazone (0, 0.1, 1, and 5µM) and wound closure was monitored and photographed at time points 
(0, 6, and 12 hours).  B.  15d-PGJ2 decreases wound closure at 12 hours.  Ciglitazone and 15d-PGJ2 treatments 
significantly decreased wound closure.  **(p< 0.01). 
 
 
 
 
 
 
 
[15d-PGJ2] (µM) 
[ciglitazone] (µM) 
A. 
B. 
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were mediated by PPAR-γ, we pretreated the cells with the PPAR-γ specific antagonist 
GW9662.  Interestingly, blocking PPAR-γ activation with GW9662 (5 µM) pretreatment did 
not reverse the effect of ciglitazone (5 µM) in either cell line. The data suggest ciglitazone is 
working in a PPAR-γ independent manner to reduce cell migration.  The effect of ciglitazone 
on cell viability was determined by MTT.  Treatment of MCF-10A and MCF-10CA1 cells 
with up to 5 µM ciglitazone did not significantly reduce cell viability (Figure 4.3).  These 
results imply the effect we see in MCF-10A and MCF-10CA1 cell motility is not mediated 
through a reduction in cell viability.       
 
Ciglitazone treatment decreases PAI-1 levels in MCF-10A and MCF-10CA1 cells 
 Several studies have shown treatment of a variety of cell types with various TZDs 
alter PAI-1 expression.  While the reports are conflicting, there is much evidence     
suggesting PPAR-γ ligands can regulate PAI-1 expression.  In both MCF-10A and MCF-
10CA1 cell lines, ciglitazone treatment resulted in decreased PAI-1 protein expression 
(Figure 4.4A).  To determine if this decrease in PAI-1 expression was mediated by PPAR-γ, 
we pretreated with GW9662 prior to ciglitazone treatment.  We did not see a reversal of 
ciglitazone mediated reduction in PAI-1 expression (Figure 4.4B) suggesting ciglitazone is 
affecting PAI-1 levels independently of PPAR-γ.     
 
Ciglitazone treatment alters uPA activity on cell surface   
 Since PAI-1 inhibits uPA activity, and ciglitazone treatment reduces PAI-1 
expression, we next investigated cell-associated uPA activity following treatment with  
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Figure 4.2.  Ciglitazone decreases chemotaxis in MCF-10A and MCF-10CA1 cells.  (A.)  
MCF-10A cells and (B.)  MCF-10CA1 cells were pretreated with GW9662 (5µM) or vehicle control (DMSO) 
for 30 minutes, followed by ciglitazone (5µM) or vehicle control (ethanol).  Cells were trypsinized and 
resuspended in DMEM:F12 containing 1mg/ml fatty acid free BSA.  1.0 X 105 cells were plated in upper wells 
of chemotaxis chamber, above a collagen IV coated 10mm porated nitrocellulose membrane.  Cells chemotaxed 
to 5ng/ml EGF in 1mg/ml fatty acid free BSA in DMEM:F12 or 1mg/ml fatty-acid free BSA in DMEM:F12 
alone for 6-hours at 37˚C.  Cells were then fixed and stained.  The membrane was placed on a glass slide 
bottom side down, and cells remaining on top of membrane were removed.  Another slide was placed on top of 
membrane and sealed.  The number of cells in four fields per well were counted.  Each condition was done in 
triplicate.  Values represent total number of cells per well + SD (n=3).  *= p< 0.05.           
A. 
* 
* 
* 
B. 
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Figure 4.3.  Concentrations of ciglitazone up to 5 µM do not significantly reduce cell 
viability in MCF-10A and MCF-10CA1 cells.  (A.) MCF-10A and (B.) MCF-10CA1 cells were 
plated at 1.0 X 104 cells per well in 96-well plates.  Cells were allowed to adhere overnight, then serum-starved 
for 24-hours.  Following serum-starvation, cells were treated with ciglitazone (0µM, 1µM, 5µM, and 10µM) in 
serum-free media for 24-hours.  MTT reagent was then added to cells and incubated at 37C for 2-hours.  DMSO 
was added to cells and incubated at 37˚C for 30 minutes.  Absorbance was read at 595nm, each condition was 
done in triplicate.  Values represent average Ab 595 nm + SD (n=3).   
 
 
B. 
A. 
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ciglitazone.  Interestingly, in MCF-10A cells ciglitazone treatment alone or in conjunction 
with GW9662 pretreatment, increases uPA activity on the cells surface (Figure 4.5A).  
Ciglitazone treatment in MCF-10CA1 cells did not significantly alter uPA activity, although 
it seems GW9662 treatment in these cells results in more plasmin generation (Figure 4.5B). 
 
Arachidonic acid increases MCF-10A cell motility in a PPAR-γ dependent manner  
Since ArA has been implicated in cancer cell biology in prostate and breast cancer, 
we next studied the effects of ArA on MCF-10A cell motility.  With 10 mM ArA, we see a 
significant increase in cell motility compared to control cells (Figure 4.6A).  When we 
pretreated the MCF-10A cells with the PPAR-γ antagonist GW9662, we see a reduction in 
cell motility (Figure 4.6A).  These results suggest ArA is able to activate PPAR-γ, resulting 
in increased cell motility.  We then measured uPA activity in MCF-10A cells and saw ArA 
treatment increases uPA activity on the cell surface, though GW9662 did not seem to reduce 
the uPA activity (Figure 4.6B).  Interestingly, the results show ArA, through PPAR-γ, can 
modulate cell motility in these cells, though the ArA induced increase in uPA activity may 
not be mediated by PPAR-γ activity.  Treatment with the ω-3 fatty acid DhA, up to 5 µM, 
had no effect on cell motility (data not shown).  
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Figure 4.5.  Ciglitazone treatment increases uPA activity in MCF-10A cells.  A.  Amiloride 
treatment decreases cell-associated uPA activity.  Following 24-hour treatment, MCF-10CA1 cells treated with 
amiloride (200 µM) were able to generated less plasmin.  Media was removed from cells, washed in 1X PBS 
and plasminogen was then added.  After 30-minutes at room temperature, cell supernatant was transferred to 
wells containing plasmin chromogenic substrate (S-2251, Chromogenix).  Kinetics were read at 405 nm for 1.5-
hours at 37˚C.  Values represent average Vmax at Ab 405 nm, normalized to no treatment control, each 
condition done in triplicate (n=3). *p<0.05.   
 
 
A. 
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* 
* 
* 
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Figure 4.6.  Arachidonic acid treatment increases
activity.  A.  MCF-10A cells were treated for 24
control (absolute ethanol in DMEM:F12 containing 1mg/ml fatty acid
pretreatment with GW9662 (5 µM) or vehicle (DMSO).  Following treatment, cells were trypsinized and 
resuspended in DMEM:F12 containing 1mg/ml fatty acid
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plasminogen (3mg) for 30 minutes at room temperature.  Supernatant from cells was transferred to a new well 
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B.
A.
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Discussion 
 For years, PAI-1 and uPA protein expression have been used as strong independent 
prognostic indicators for breast cancer [74,168,193,194].  Because PAI-1 and uPA 
overexpression are so tightly correlated with patient prognosis in breast cancer, it is 
important to investigate agents which alter expression of either of these components of the 
PA system.  In addition to cancer, PAI-1 overexpression is linked to a variety of disease 
states.  Morbidly obese individuals have elevated circulating PAI-1 levels, likely due to an 
increase in PAI-1 expression from adipose tissue [84].  In rats with streptozocin-induced 
diabetes, PAI-1 levels are increased 60-80% over control [195].  In humans, elevated PAI-1 
levels have been reported in patients with type 2 diabetes mellitus (T2DM) [81], and is 
related to cardiovascular dysfunction [81,108].  While the function of PPAR-γ in a tumor 
setting is unknown, our interest in PPAR-γ in breast cancer is based on literature that shows 
PPAR-γ regulates PAI-1 expression.  While the literature on PPAR-γ activation and PAI-1 
alterations is conflicting, it has been shown in a number of cell types and in vivo that PPAR-γ 
does modulate PAI-1 expression [52,53,108,109].  We treated cells with ciglitazone, 15d-
PGJ2 and arachidonic acid to investigate effects of PPAR-γ activation on migration and PAI-
1 expression following treatment.  Based on previous literature, we expected to see 
differential effects of PPAR-γ activation, specifically with ArA treatment [131]. 
 In vitro, treatment of tumor cells with TZDs results in a number of anti-tumor effects.  
In prostate cancer cells, PPAR-γ ligands reduced proliferation, induced terminal 
differentiation, downregulated E-cadherin and c-myc expression [187].  Another group 
showed pioglitazone, in combination with valproic acid, upregulates E-cadherin and reduced 
invasion and migration in prostate cancer cells [196].  In vitro wounding assays were done to 
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determine if treatment with PPAR-γ agonists would alter MCF-10A cell migration.  
Treatment with both ciglitazone and 15d-PGJ2 resulted in a significant decrease in wound 
closure over a 12-hour period of time.   
 We next chose to investigate directed migration following treatment with ciglitazone.  
Directed migration, or chemotaxis, is an important part of tumor cell biology, causing a cell 
to respond to a distant signal and leave its site of origin.  The modified-Boyden chamber 
model utilizes directed migration toward a chemoattractant, in our case epidermal growth 
factor (EGF).  Ciglitazone treatment decreased chemotaxis toward EGF in both the MCF-
10A and MCF-10CA1 cells.  GW9662 is a specific PPAR-γ antagonist, which binds PPAR-γ 
and blocks ligand binding and subsequent activation of the receptor [197].  Surprisingly, 
pretreatment with GW9662 did not reverse the effects of ciglitazone.  These results lead us to 
suspect ciglitazone mediates this reduction in migration through a PPAR-γ independent 
mechanism.  Although ciglitazone is considered a specific PPAR-γ agonist, several PPAR-γ-
independent effects of ciglitazone, and other PPAR-γ ligands, have been reported.  Emery, et 
al. showed rosiglitazone and pioglitazone inhibited proliferation of pituitary tumors.  
Treatment with PPAR-γ antagonist did not reverse these effects either, suggesting the anti-
proliferative effects of these drugs was independent of PPAR-γ activation [117].  Another 
study found ciglitazone and 15d-PGJ2 induced apoptosis in normal and malignant B cell, 
independent of PPAR-γ [198].  Finally, ciglitazone and 15d-PGJ2 have been shown to 
activate p38 MAPK signaling, which were reported to be independent of PPAR-γ activation 
[199,200]. 
 Interestingly, ArA treatment of MCF-10A cells resulted in an enhancement of cell 
migration.  These effects were reversed in cells pretreated with GW9662, suggesting ArA is 
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acting in a PPAR-γ dependent manner.  Since ω-3 and ω-6 fatty acids have been shown to 
have differential effects on PPAR-γ activation [131], we also investigated if ω-3 fatty acids 
had an effect on cell migration in our system.  Surprisingly, we saw no change in migration 
in MCF-10A cells treated with DhA, supporting the literature which says ω-6, but not ω-3, 
fatty acids promote cell motility [201].  While we see little effect of GW9662 pretreatment 
on ArA induced uPA activity, one possible explanation for this is that ArA also signals 
through PI3K [129], which upregulates uPA activity and expression [172].  It is possible ArA 
is engaging PPAR-γ intracellularly, resulting in increased cell migration, while independently 
initiating the PI3K signaling cascade and upregulating uPA activity.         
PPAR-γ and its synthetic ligands have been implicated in the regulation of PAI-1 
expression.  One in vitro study reports TZD treatment of adipocytes induces PAI-1 
expression [52].  In vivo, type 2 diabetes mellitus (T2DM) patients had a significant decrease 
in circulating PAI-1 levels following a 5-month treatment with the PPAR-γ agonist 
rosiglitazone [52,108].  Another in vivo study noted a reduction in PAI-1 level in both T2DM 
patients following rosiglitazone treatment [109].  Based on the data described in this chapter, 
and the in vivo literature from TZD treated T2DM patients, these drugs appear to regulate 
PAI-1 expression, possibly through a PPAR-γ independent mechanism.  
TZDs may be useful adjuvant therapies in breast cancer treatment.  Based on the 
literature suggesting TZDs induce apoptosis, decrease cell proliferation and induce terminal 
differentiation in breast cancer cells in vitro and in vivo, some clinical trials have been 
designed to determine if TZDs provide any benefit as part of a treatment regimen in cancer 
patients.  A phase I clinical trial investigated the maximum tolerated dose of rosiglitazone in 
combination with bexarotene, a ligand for RXR, for treatment of refractory breast cancer 
  
72 
 
[121].  While there was no dose-limiting toxicity reported at the completion of that study, 
there appeared to be no measurable effect of rosiglitazone treatment in patients [121].  
Another clinical trial in phase-two investigated the effect of pioglitazone in conjunction with 
a COX-2 inhibitor in glioma patients, and saw moderate results in patients with high-grade 
glioma, suggesting pioglitazone treatment may be beneficial to a subset of patients [202].  A 
phase-I trial of a non-TZD PPAR-γ agonist LY29311 studied maximum tolerated dose in a 
combination regimen in patients with advanced solid tumors, and determined there was no 
limiting toxicity and no disease progression [203].  A phase-II study was recommended at 
completion of this trial.  Prior to being removed from commercial availability, troglitazone 
was in a phase-II clinical trial for treatment of refractory breast cancer [120].  At suspension 
of the trial, no clinical value was noted in the patients receiving troglitazone over control.  
While these clinical trials suggest PPAR-γ agonist show little benefit in patients with 
diagnosed disease, there is literature to suggest PPAR-γ agonist may have some preventative 
benefits in diabetic patients.    
While PPAR-γ agonist have shown little effect in clinical trials, it is possible there 
may be some preventative effects.  One study shows diabetic patients being treated with 
TZDs have lower incidence rates of cancer, specifically lung cancer [204].  This study was 
designed around male T2DM patients, and breast cancer incidence was not investigated.  
Another retrospective case study identified over 14,000 diabetic patients receiving TZD 
treatment for greater than one year and found an inverse relationship between TZD use and 
incidence of colon cancer, found at time of colonoscopy [205].  One meta-analysis of clinical 
trial data of rosiglitazone found no difference in proportion of cancers in rosiglitazone groups 
from control groups as reported in clinical trials [206], disputing reports that TZD treatment 
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increases cancer incidence in diabetic patients [207].  To date no clear protective effect of 
TZD treatment and cancer risk in diabetic patients has been found, though it has been shown 
that TZD therapies are not associated with a higher risk of developing cancer than other 
antidiabetic treatments.  It should be noted that metformin, a widely prescribed antidiabetic is 
associated with decreased risk of cancer [208], and the meta-analysis included several 
clinical trials comparing rosiglitazone to metformin and found no difference in cancer 
prevalence [209].  If there is a possible preventative effect of PPAR-γ agonists, it is probable 
diabetic patients may eventually have reduced risk of cancer development, including breast 
cancer.  
This study shows ciglitazone treatment reduces both normal and malignant epithelial 
cell migration in vitro, independently of PPAR-γ activation.  Additionally, we found 
ciglitazone treatment reduces PAI-1 protein levels, and this effect was not reversed by 
antagonism of PPAR-γ.  We hypothesize that the anti-migratory effects of ciglitazone are 
mediated by the alteration of the PA system in these cells.  We know PAI-1 inhibits 
apoptosis, can promote cell motility and plays a role in intracellular signaling.  Given the role 
of PAI-1 in these tumor processes, the in vivo data showing FDA approved TZDs decrease 
PAI-1 in diabetic patients, and our results, one could draw the conclusion that TZD therapies 
may prove to be a valid adjuvant therapy for some breast cancer patients.  Since our data 
shows a potent PPAR-γ independent effect of ciglitazone on cell migration and PAI-1 
expression, it will be important for future therapeutic design to gain a full understanding of 
ciglitazone and other TZD drugs mechanism of action.                       
 
  
 
Chapter V 
 
Role of Adipocytes in Breast Cancer Progression 
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Abstract 
In addition to their role as energy stores, adipocytes express a number of cytokines 
involved in both normal physiology and pathological processes.  One such cytokine with 
elevated plasma levels in obese humans and mice is plasminogen activator inhibitor type-1 
(PAI-1).  PAI-1 functions to inhibit urokinase type plasminogen activator (uPA) though PAI-
1 itself is also implicated in breast cancer progression.  While the role of adipocytes in breast 
cancer development is not fully understood, obesity is a risk factor associated with breast 
cancer.  Thus, we became interested in characterizing the plasminogen activator system in 
adipocytes from various fat depots, and their influence on breast cancer motility.  Using 
preadipocyte cells from breast and omental adipose tissue, we were able to differentiate each 
site into mature adipocytes.  uPA protein was not detected in any cell type, although PAI-1 
expression was detected and it varied based on location of adipose tissue, in decreasing order 
for breast adipocytes, omental preadipocytes, omental adipocytes, and breast preadipocytes, 
respectively.  We studied the effect of breast adipocytes and their precursor cells on both 
normal (MCF-10A) and malignant (MCF-10CA1) breast epithelial cell lines.  Using 
differentiated mature adipocytes, we found that breast adipocytes, but not preadipocytes, 
increased cell motility in the MCF-10A and MCF-10CA1 cell lines.  We also found an 
increase in phosphorylated AKT levels following treatment of MCF-10CA1 cells with 
conditioned media (CM) from adipocytes, but not the preadipocytes.  Gene array profiling 
indicates adipocyte conditioned media alters expression of several genes associated with 
cancer, including the urokinase receptor (uPAR).  Our results show mature breast adipocytes 
alter the epithelial cell phenotype, producing a more motile cell type.  These data provide a 
potential link between obesity and risk of breast cancer.      
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Introduction 
In the United States, there has been a significant increase in overweight and obese 
adults in the past twenty years [3,210].  In 2005-2006, adult obesity was reported to be 33.3% 
in men, and 35.4% in women [210].  Childhood overweight and obesity statistics have also 
shown a dramatic increase in recent years [211,212].  As the number of overweight and 
obese children increases, there is growing concern that they will remain overweight or obese 
into adulthood.  Since obesity is associated with a number of diseases, these statistics are 
particularly shocking.  Obesity has been associated with increased risk of cardiovascular 
disease, diabetes, and cancer.  Obesity is characterized by hypertrophy of adipocytes and a 
dysregulation in adipokine secretions [104,213,214].  Obesity has been correlated to risk of 
development of colon, ovarian and breast cancers [124,215--217].         
Adipocytes are located in various sites, or fat depots, throughout the human body.  In 
the breast, a large percentage of the cells are adipocytes or adipocyte precursor cells.  In 
recent years, other fat depots, such as the omentum, have been cited in the literature as being 
metabolically active cells, as well as cells involved in paracrine signaling [84,88,104,218].  
Historically, adipocytes are thought of as energy stores in the body, but now they are known 
to be involved in a number of pathological processes, including inflammation.  It is this role 
in inflammation that lead to us investigate the effect of adipocytes in the tumor 
microenvironment on cell motility and gene expression.   
Adipocytes express a number of pro-inflammatory cytokines, including tumor 
necrosis factor-α and PAI-1, which is overexpressed in obese individuals [84,86,87].  PAI-1 
is a 47 kDa serine protease inhibitor (serpin), which functions to inhibit the plasminogen 
activators.  Though PAI-1 is involved normal hemostasis, elevated PAI-1 is a marker for 
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cardiovascular disease and is involved in pathogenic thrombus formation [219].  PAI-1 has 
been shown to be expressed in adipose tissue, though there is no consensus in the literature 
on what cell in that heterogeneous tissue expresses the protein.  A number of studies suggest 
PAI-1 is expressed in the fibroblast precursor cells [220,221], while others indicate PAI-1 is 
expressed mainly in the mature adipocyte [104].  Our research suggests that PAI-1 may be 
differentially expressed in cultured cells of adipose tissue based on what anatomic location 
they were harvested from.     
Since elevated plasma levels of PAI-1 are seen in obese individuals, we hypothesized 
that excess PAI-1 from adipose tissue could contribute to a tumorigenic phenotype in breast 
epithelial cells, and possibly potentiate the tumor phenotype of malignant breast epithelial 
cells.  Given the inhibitory role of PAI-1 to block extracellular matrix degradation through 
inhibition of urokinase plasminogen activator, it is not well understood what mechanism 
drives PAI-1 to increase motility and cell survival in breast cancer.  The breast is a very 
heterogeneous tissue, comprised of epithelial cells, fibroblasts and adipocytes [2], and we are 
interested in what role the breast adipocytes play in breast cancer progression.  We 
investigated if exposure to adipocytes created a more aggressive phenotype in breast 
epithelial cells.  Using the normal cell line, MCF-10A and the invasive carcinoma cell line, 
MCF-10CA1, we were able to show that adipocytes do mediate an effect in normal cells, 
implicating adipocytes in the development of breast cancer.     
 
 
 
 
  
78 
 
Materials and methods 
Cell culture 
Breast preadipocytes (ZenBio, RTP, NC) were plated in six-well TC plates (Corning, 
Lowell, MA), and propagated in preadipocyte media (ZenBio, RTP, NC) at 37˚C in a 
humidified atmosphere of 5% CO2.  Confluent preadipocytes were then propagated in 
differentiation media (ZenBio, RTP, NC) for 7 days.  Following the differentiation media, 
the resulting adipocytes were propagated in DMEM:F12 (GIBCO®, Invitrogen, Carlsbad, 
CA) containing 1% PSF (GIBCO®, Invitrogen, Carlsbad, CA), 10% fetal bovine serum 
(Sigma, St. Louis, MO), and 5ng/ml insulin (GIBCO®, Invitrogen, Carlsbad, CA) for seven 
days.  Omental preadipocytes were cultured in omental preadipocyte media (ZenBio, RTP, 
NC).  Omental adipocytes were differentiated for 7 days in omental differentiation media 
(ZenBio, RTP, NC), then maintained in omental adipocyte maintenance media (ZenBio, 
RTP, NC).  Preadipocytes and mature adipocytes from breast and omentum were serum-
starved in DMEM:F12 (GIBCO®, Invitrogen, Carlsbad, CA) containing 1% PSF (GIBCO®, 
Invitrogen, Carlsbad, CA) for 24 hrs, and conditioned media was stored at -20˚C until 
needed.  MCF-10A and MCF-10CA1 cells (from F. Miller, Wayne State University, Detroit, 
MI) were cultured in DMEM:F12 (GIBCO®, Invitrogen, Carlsbad, CA) containing 5% horse 
serum (HyClone, Logan, UT), 1% PSF (GIBCO®, Invitrogen, Carlsbad, CA), 20 µg/ml EGF 
(Invitrogen, Carlsbad, CA), 50 ng/ml hydrocortisone, 100 ng/ml cholera toxin (CalBiochem, 
San Diego, CA) and 10 µg/ml insulin (GIBCO®,Invitrogen, Carlsbad, CA).  Cells were 
grown in a humidified atmosphere of 5% CO2 at 37˚C.  
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Immunoblot analysis 
Conditioned media was concentrated (Millipore, Billerica, MA).  Cells were rinsed in 
ice-cold PBS and lysed on ice for 20 minutes, in buffer containing 50mM Tris, 0.1% sodium 
dodecyl sulfate (SDS), 150mM NaCl, 1mM PMSF, 1mM EDTA, 1% Triton X-100, 1% Na 
deoxycholate, 5µg/ml aprotinin, and 5µg/ml leupeptin.  Lysed cells were centrifuged at 
14000 X g for 5 minutes at 4˚C.  Protein concentration was determined using BioRad Protein 
DC assay (BioRad, Hercules, CA).  Proteins were separated by SDS-PAGE in 10% 
polyacrylamide and electrotransfered to PVDF membrane.  Phosphate buffered saline/0.1% 
Tween-20 (PBS/Tween) buffer was used in all steps of immunoblot analysis.  Each step was 
preceded by three 9-minute washes at room temperature.  Non-specific binding was blocked 
by 5% nonfat dry milk for 30 minutes at room temperature.  Membrane was incubated at 4˚C 
overnight with primary antibody diluted 1:1000 (unless otherwise noted) in 1% nonfat dry 
milk.  Membrane was exposed for 1 hour at room temperature to horseradish peroxidase 
conjugated secondary antibody diluted 1:5000 in 1% nonfat dry milk in PBS/Tween.  
Membrane was exposed to luminal substrate for 1 minute, covered in plastic wrap then 
exposed to X-ray film.  Primary antibodies were rabbit anti-human PAI-1 (1:2000 dilution) 
(Molecular Innovations, Novi, MI), rabbit anti-uPA (#389, American Diagnostica, Stamford, 
CT), rabbit anti-human phosphorylated-Akt (Ser473) (9721, Cell Signaling, Danvers, MA) 
and rabbit anti-human total Akt (9722, Cell Signaling, Danvers, MA).     
      
Modified-Boyden Chamber assay 
MCF-10A and MCF-10CA1 cells were serum-starved overnight.  Cells were then 
treated with CM from preadipocytes and mature adipocytes for 24 hours.  Following 
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treatment, cells were pelleted and resuspended in DMEM:F12 (GIBCO®, Invitrogen, 
Carlsbad, CA)  supplemented with 1% fatty-acid free bovine serum albumin (BSA, Sigma, 
St. Louis, MO).  Chemotaxis was to 5ng/ml EGF in DMEM:F12 supplemented with 1% fatty 
acid free BSA.  Cells were plated in 48-well chamber (Neuro Probe, Gaithersburg, MD) 
above a collagen IV (Sigma, St. Louis, MO) coated 10µm porated PVP-PCTE membrane 
(Neuro Probe, Gaithersburg, MD).  Cells migrated for 6 hours at 37˚C.  Following 
incubation, the membrane was removed from plates and cells attached to the membrane were 
stained with Diff-Quick (Dade-Behring, Newark, DE).  The membrane was them sandwiched 
between two glass slides.  For analysis, cells in 4 central fields were counted and averaged, 
n=3. 
 
Indirect cell-surface plasminogen activator activity assay 
Cells (1 X 104) were plated in 96-well plates.  Confluent cells were serum-starved 
overnight.  Cells were incubated in various treatments for 24 hours.  Following treatment, 
cells were washed with PBS.  Plasminogen was diluted in Tris buffer (pH 8.8) containing 
0.5% Triton X-100.  Plasminogen (3 µg) and buffer were then added to cells and incubated at 
room temperature for 30 minutes.  Following incubation, supernatant was transferred from 
cells to new 96-well plate containing amiloride (6 mM) and buffer.  Plasmin chromogenic 
substrate (S-2251, Chromogenix, Milan, Italy) was then added to wells and Vmax at 405nm 
was measured over 90 minutes at 37˚C using a ThermoMax (Molecular Devices, Sunnyvale, 
CA) plate reader.  Treatments were done in triplicate, n=3.  Results were normalized to 
untreated control.  
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Cell viability assay 
MCF-10A and MCF-10CA1 cells were plated at 1.0x104 cells per well in a 96-well 
tissue culture plate.  Confluent cells were serum-starved 24 hours then treated with MCF-
10A serum-free media, preadipocyte serum free media, preadipocyte conditioned media, or 
adipocyte conditioned media.  Following incubation, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) reagent (Sigma, St. Louis, MO) was added to cells, and 
incubated at 37˚C for 3 hours.  Supernatant was removed and cells were washed in PBS.  
DMSO was added to cells and incubated at 37˚C for 30 minutes.  Absorbance was measured 
(Ab=595nm) on a SpectraMax microplate reader (Molecular Devices, Sunnyvale, CA). 
 
RT2 Profiler™ PCR Array 
 Serum-starved MCF-10A and MCF-10CA1 cells were treated with adipocyte and 
preadipocyte conditioned media for 24-hours.  RNA was isolated from cells using the 
RNeasy Plus Mini Kit (Qiagen, Valencia, CA) according to manufacturer’s protocol.  One µg 
RNA was converted to cDNA with the RT2 First Strand Kit (SA Biosciences, Frederick, MD) 
according to manufacturer’s protocol.  Gene expression profiling was performed using the 
Cancer Pathway Finder RT2 Profiler PCR Array (SA Biosciences, Frederick, MD) and RT2 
qPCR Master Mix (SA Biosciences, Frederick, MD).  Reaction was run using the ABI 7500 
(Applied Biosystems, Foster City, CA).  Reaction set-up was: 95˚C for 10 minutes, 40 cycles 
of 95˚C for 15 seconds and 60˚C for 1 minute, followed by a dissociation curve.  At 
completion of reaction, the threshold was manually set and Ct was determined.  ∆∆Ct and 
fold-change was determined using the RT2 Profiler PCR Array Data Analysis web portal 
(http://www.sabiosciences.com/pcr/arrayanalysis.php, SA Biosciences, Frederick, MD).   
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Results 
Characterization of PA system in preadipocytes and adipocytes 
In examining the effect of adipocytes on breast cancer motility, we were interested in 
understanding the differences in the PA system components between mature adipocytes and 
their precursor cells (Figure 5.1).  While it has been reported in the literature that PAI-1 is 
expressed in the adipose tissue, there is little known about uPA expression.  In breast 
adipocyte conditioned media, PAI-1 was highly expressed, while little to no PAI-1 protein 
was expressed in the precursor cell (Figure 5.2).  Using immunoblot analysis, uPA protein 
expression was not found in any adipocyte cell type (data not shown).   
The literature is replete with references to PAI-1 expression in adipose tissue, 
although there is no consensus as to which cell in the adipose tissue expresses the bulk of the 
PAI-1 secreted.  It should also be noted that adipose from one fat depot often has varied 
characteristics when compared to adipose from another site.  Therefore, we examined PAI-1 
levels in adipocyte and their precursor cells from omental adipose tissue.  Interestingly, PAI-
1 levels were higher in omental preadipocytes than in the mature adipocytes (Figure 5.2), and 
uPA was absent from both cell types (data not shown).  Omental adipose tissue has been 
reported to be the fat depot with the most negative effects on health.  It is a large producer of 
a number of inflammatory cytokines, and visceral adipose tissue has been reported to be the 
main source of the excess plasma PAI-1 in obese individuals.  In our system, the mature 
breast adipocytes secreted significantly more PAI-1 compared to omental preadipocytes and 
adipocytes.      
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Figure 5.1.  BRF1 primary human preadipocytes and differentiated mature adipocytes.  
A.  BRF1 human breast preadipocytes, 100X magnification.  B.  BRF1 human breast mature adipocyte, day 14 
post differention, 100X magnification.  Cells were grown to confluence in Preadipocyte maintenance media 
(ZenBio, RTP, NC).  Cells were cultured in differentiation media (ZenBio, RTP, NC) for 7 days, followed by 
maintenance media (DMEM:F12 containing 1%PSF, 10% FBS, and 5ng/ml insulin) for 7 days. 
 
 
 
 
 
A. 
B. 
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Figure 5.2.  PAI-1 expression in cultured primary human preadipocytes and 
differentiated mature adipocytes.  A.  PAI-1 levels in conditioned media vary based on cell type and 
location of primary fat depot (BRF1 preadipocytes, BRF1 adipocytes, omental preadipocytes, and omental 
adipocytes, respectively).  Cells were serum starved for 24 hours upon reaching confluence (preadipocytes) or 
following differentiation (adipocytes).  Conditioned media was collected and concentrated in centrifugal 
concentrator.  10µg total protein (BRF1 preadipocyte CM, BRF1 adipocyte CM, omental preadipocyte CM, and 
omental adipocyte CM, respectively) was loaded for each sample.  Membrane was probed for human PAI-1 
(1:2000 rabbit anti-human PAI-1, ASHPAI, Molecular Innovations, Stamford, CT).  B.  Quantification of 
immunoblot analysis of PAI-1 levels (n=3).      
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Adipocyte conditioned media increases cell motility 
In examining the effect of adipose tissue on breast epithelial motility, we compared 
adipocyte to preadipocyte conditioned media.  Using the modified-Boyden chamber model, 
we first used the conditioned media as the chemoattractant, to determine if mature adipocytes 
secreted a factor that MCF-10A cells chemotaxed to preferentially over preadipocytes.  There 
was no change in number of cells that migrated to preadipocyte conditioned media compared 
to cells that chemotaxed to adipocyte conditioned media (Figure 5.3).  We next examined the 
effect of treating MCF-10A cells with conditioned media from either the preadipocytes or 
adipocyte.  After a 24-hour incubation, the cells were plated in the modified-Boyden 
chamber model, and allowed to chemotax to either EGF or BSA control.  Treatment with 
adipocyte CM resulted in a two-fold increase in cell motility to EGF (Figure 5.3).  There was 
no increase in cell motility following treatment with preadipocyte conditioned media.  
Similar results were seen with the invasive MCF-10CA1 cell line, with a 1.5-fold increase in 
cell motility to EGF following treatment with adipocyte conditioned media (Figure 5.3).   
 
Adipocyte conditioned media increases phosphorylated-Akt levels in MCF-10CA cells 
The phosphatidylinositol-3 kinase (PI3K) pathway is implicated in cancer cell 
biology, both increasing cell motility and negatively regulating apoptosis [174,175,222,223].  
Increases in phosphorylated Akt, a signaling molecule downstream of PI3K, is found in a 
number of breast cancer cell lines.  We wanted to determine if the increase in cell motility we 
saw in MCF-10CA cells following treatment with adipocyte CM was a result of increased  
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Figure 5.3.  Adipocyte conditioned media treatment increases cell motility.  (A.) MCF-10A 
cell chemotaxis to EGF was increased 1.7-fold.  (B.) MCF-10CA1 cell chemotaxis to EGF was increased 1.5-
fold.  Cells were treated for 24-hours with serum-free media, preadipocyte conditioned media, and adipocyte 
conditioned media.  Following treatment, cells were washed, trypsinized, and resuspended at 2.0 X 106 cells per 
milliliter in DMEM:F12 containing 1mg/ml fatty-acid free BSA.  1.0 X 105 cells were then plated in chemotaxis 
chamber upper wells above a 10µm porated collagen IV-coated membrane and incubated at 37˚C for 6 hours, 
chemotaxing to EGF (5ng/ml) or DMEM:F12 containing 1mg/ml fatty acid free BSA.  Following incubation, 
cells were fixed, stained and membrane was placed between glass slides.  Cells were counted in 4 fields per 
well.  Values represent average number of cells per well + SD (n=3).  *= p<0.05 
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phosphorylation of Akt.  We treated the cells with adipocyte or preadipocyte CM for 24-
hours.  Following 24-hour incubation with adipocyte of preadipocyte CM, immunoblot 
analysis of MCF-10CA1cell lysates was used to examine phosporylated Akt levels.  
Treatment with adipocyte CM resulted in an increase in phospho-Akt levels in MCF-10CA1 
cells (Figure 5.4).  MCF-10A cells express little to no phospho-Akt at steady state, and levels 
were undetectable in all treatment conditions.   
  
Adipocytes increase cell-surface uPA activity 
Our lab has previously shown PI3K activity can both upregulate uPA expression and 
decrease PAI-1 expression.  Since uPA activity has been implicated in cell motility, we 
investigated the effects of treating MCF-10A and MCF-10CA1 cells with adipocyte CM on 
plasmin cleavage.  While the adipocyte CM expressed significantly greater levels of PAI-1, 
following adipocyte CM treatment, the cells were able to cleave more plasminogen to 
plasmin then those treated with preadipocyte CM or the non-conditioned serum-free media 
(Figure 5.5).  These results imply some factor in the conditioned media is triggering 
increased uPA activity, either through increased uPA expression or reduced PAI-1 
expression, which may be responsible for the increase in motility in both cell lines. 
 
  
  
88 
 
 
Figure 5.4.  Phosho-Akt levels increase in MCF-10CA1s treated with adipocyte 
conditioned media for 24 hours.  A. 10 µg total cell lysate (preadipocyte SFM treated, preadipocyte 
CM treated, and adipocyte CM treated, respectively) was separated on 10% SDS-PAGE.  Protein was 
transferred to membrane and immunoblot analysis was done using rabbit anti-human phospho-Akt (Ser 473) 
(#9721, Cell Signaling, Danvers, MA) and rabbit anti-human total-Akt (#9722, Cell Signaling, Danvers, MA).  
Primary antibody dilutions were 1:1000.  HRP-conjugated secondary antibody dilution was 1:5000, and was 
detected with enhanced chemiluminescence.  B.  Phospho-Akt expression was quantified relative to total-Akt 
expression (n=3). 
   
 
 
IB: phospho-Akt 
IB: Total Akt 
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Adipocyte conditioned media alters expression of cancer related genes in MCF-10A and 
MCF-10CA1 cells 
 Using a targeted real-time PCR array for cancer related genes, we found a number of 
genes with altered expression in MCF-10A (Table 5.1) and MCF-10CA1 (Table 5.2) cell 
lines following treatment with adipocyte conditioned media compared to preadipocyte 
conditioned media treatment.  uPAR and PI3KR1 expression was elevated in MCF-10A cells 
following adipocyte treatment, 2.16-fold and 2.37-fold respectively.  In MCF-10CA1 cells 
treated with adipocyte conditioned media, we saw a 1.77-fold increase in PAI-1 expression.  
MMP1, a collagenase, was downregulated in both MCF-10A (-14.40-fold) and MCF-10CA1 
(-5.33-fold) following treatment with adipocyte conditioned media compared to preadipocyte 
conditioned media treatment.  In MCF-10A cells, we also saw down-regulated expression of 
several genes involved in angiogenesis, including fibroblast growth factor receptor-2 (-3.38-
fold), interferon α (-2.08-fold), and platelet-derived growth factor β peptide (-2.19-fold).  
Additionally, BCL2 (-2.02-fold) was also down-regulated in MCF-10A cells.  In MCF-
10CA1 cells, angiopoietin-1 was down-regulated 2.01-fold, while transforming growth factor 
b-1 was upregulated 1.78-fold.  Following treatment with adipocyte conditioned media, Myc 
and Jun were upregulated in the MCF-10CA1 cells (1.97-fold and 1.86-fold, respectively).     
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Figure 5.5.  Treatment of MCF-10A and MCF-10CA1 with adipocyte conditioned 
media increases cell-surface uPA activity.  MCF-10A and MCF-10CA1 cells were plated at 1.0 X 
104 cells per well in a 96-well plate and grown to confluence.  Cells were then serum starved overnight and 
followed by a 24 hour treatment with BRF1 adipocyte CM or BRF1 preadipocyte CM.  Following treatment, 
cells were washed in PBS and incubated at room temperature in buffer containing plasminogen for 30 minutes.  
Supernatant from cells was removed and added to wells containing buffer and amiloride.  Plasmin chromogenic 
substrate was added to wells.  Kinetics were read at Ab 405nm for 1.5 hours at 37C.  Values represent average 
Vmax (Ab 405nm) normalized to Preadipocyte SFM treatment control + SD (n=3).  **=p<0.01, *=p<0.05. 
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Table 5.1- Alterations in gene expression in MCF-10A cells following treatment with adipocyte 
conditioned media* 
Gene designation Gene name Fold change  
 Adhesion  
ITGA2 
ITGB5 
Integrin α2 subunit 
Integrin β5 subunit 
 
-1.79 
-2.28 
 
MMP1 
Invasion and metastasis 
Matrix metalloproteinase 1 
 
-14.40 
MMP2  Matrix metalloproteinase 2 -4.45 
MMP9 Matrix metalloproteinase 9 -2.00 
PLUAR 
TIMP3 
Urokinase receptor 
Tissue inhibitor of 
metalloproteinase-3 
 
+2.16 
+3.14 
 Angiogenesis  
FGFR2 Fibroblast growth factor 
receptor 2 
-3.38 
INFA1 Interferon α -2.08 
PDGFB 
  
Platelet-derived growth factor 
β peptide 
 
Signal transduction molecules 
and transcription factors 
-2.19 
 
PI3KR1 
 
Phosphoinositol-3 kinase p85α 
regulatory subunit 
 
Apoptosis  and cell senescence 
+2.37 
 
BCL2 B-cell CLL/Lymphoma 2 -2.02 
   
*Briefly, MCF-10A cells plated in a 6-well plate, and serum-starved for 24-hours when confluent.  Cells were 
then treated with preadipocyte or adipocyte conditioned media for 24-hours.  RNA was isolated, and 1mg total 
RNA was reverse transcribed.  Real-time PCR analysis of gene expression was carried out using the RT2 
Profiler PCR Array (SA Biosciences, Gaithersburg, MD) according to manufacturer’s protocol.  Expression 
analysis was done using the RT2 Profiler PCR Array Data Analysis web portal 
(http://www.sabiosciences.com/pcr/arrayanalysis.php, SA Biosciences, Gaithersburg, MD).     
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Table 5.2- Alterations in gene expression in MCF-10CA1 cells following treatment with adipocyte 
conditioned media* 
Gene designation Gene name Fold change  
 Adhesion  
ITGA4 
ITGB3 
Integrin α4 subunit 
Integrin β3 subunit 
 
-2.16 
-1.97 
 
MMP1 
Invasion and metastasis 
Matrix metalloproteinase 1 
 
-5.53 
SERPINB5 
SERPINE1 
 
Maspin 
PAI-1 
 
+1.77 
+1.78 
 
 Angiogenesis  
ANGPT1 Angiopoietin-1 -2.01 
TGFB1 Transforming growth factor β 1 +1.78 
 
  
 
Signal transduction molecules 
and transcription factors 
 
 
JUN 
 
 
MYC 
 
v-jun sarcoma virus 17 
oncogene homolog, enhancer 
binding protein AP1 
v-myc myelocytomatosis viral 
oncogene homolog 
 
Apoptosis  and cell senescence 
+1.86 
 
 
+1.97 
 
TNFRSF25 Tumor necrosis receptor 
superfamily, member 25, death 
domain receptor 3 
+2.03 
   
   
   
*Briefly, MCF-10CA1 cells plated in a 6-well plate, and serum-starved for 24-hours when confluent.  Cells 
were then treated with preadipocyte or adipocyte conditioned media for 24-hours.  RNA was isolated, and 1mg 
total RNA was reverse transcribed.  Real-time PCR analysis of gene expression was carried out using the RT2 
Profiler PCR Array (SA Biosciences, Gaithersburg, MD) according to manufacturer’s protocol.  Expression 
analysis was done using the RT2 Profiler PCR Array Data Analysis web portal 
(http://www.sabiosciences.com/pcr/arrayanalysis.php, SA Biosciences, Gaithersburg, MD).     
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Discussion 
 While obesity has been linked with an increase in breast cancer development, there is 
little known about the mechanism by which obesity affects normal or malignant breast 
epithelial cells.  The goal of this project was to investigate the effects of adipocytes on MCF-
10A and MCF-10CA1 cell motility, and determine if adipocytes alter the expression of PA 
system components.  Using primary human breast preadipocytes, we were able to 
differentiate them to mature, lipid accumulating adipocytes.  The literature shows circulating 
PAI-1 levels are elevated in obese individuals, and this increase is likely due to adipose tissue 
secretion of a number of inflammatory cytokines, including PAI-1.  As elevated PAI-1 levels 
are associated with poor patient prognosis in breast cancer patients, adipose tissue derived 
PAI-1 may play a role in breast cancer development and progression in obese women.   
Much of the literature suggests visceral fat depots express higher levels of PAI-1, 
while subcutaneous fat depots, such as breast adipose tissue, are less significant sites of 
circulating PAI-1 [220,221,224].  Although visceral fat depots, such as the omentum, are 
believed to the main source of PAI-1, adipose tissue in the breast may locally affect tumor 
biology of breast cancer cells.  Analysis of conditioned media from preadipocytes and 
adipocytes, we saw a dramatic increase in PAI-1 expression upon differentiation in breast 
adipocytes.  In the cells from the omental fat depot, we saw elevated expression in 
preadipocytes, and a slight decrease in PAI-1 levels following differentiation.  Interestingly, 
uPA protein was not expressed in any of the cell types.  In terms of cancer, it has been widely 
hypothesized the ratio of uPA to PAI-1 is important [158,225,226], as a shift in the normal 
balance can result in a more aggressive phenotype in vitro and poor patient prognosis in vivo 
[168,193].  If adipose tissue is supplying a significant amount of PAI-1 to the tumor 
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microenvironment, it is possible the preneoplastic or neoplastic cells could benefit from the 
anti-apoptotic and pro-angiogenic roles of this excess PAI-1, in addition to the ability of PAI-
1 to increase cell motility. 
The tumor microenvironment plays an important role in cancer progression, 
supporting angiogenesis [227], proliferation of cancer cells [228], and promoting cell 
survival [229].  Carcinoma associated fibroblasts have been shown to promote epithelial to 
mesenchymal transition in breast carcinoma cells in vitro [230].  Recently, one group 
suggested a role for the PA system present in the tumor stroma of the breast as mediator of 
tumor invasion [230,231].  Since the tumor microenvironment plays an important role in 
cancer progression, it was important to investigate the effect of adipocytes and their 
precursor cells isolated from breast tissue.  Interestingly, adipocytes promoted chemotaxis in 
both normal and malignant epithelial cell lines.  Adipocyte conditioned media increased 
chemotaxis to EGF 2.0-fold and 1.5-fold in MCF-10A and MCF-10CA1 cells, respectively.  
Though the adipocyte treatment had less effect on the malignant MCF-10CA1 cell line, the 
increase was statistically significant.  The MCF-10CA1 cells are far more motile at baseline 
than MCF-10A cells, and typically, we see a more dilute effect with this cell line than we do 
in the normal MCF-10A cells.  These results support our hypothesis that adipocytes in the 
tumor microenvironment alter epithelial cells, conferring a more aggressive phenotype.   
We next investigated the molecular effects of adipocyte treatment in the MCF-10A 
and MCF-10CA1 cell lines.  Increased PI3K signaling has been implicated in cell motility, 
survival and cell proliferation [232], so we wanted to determine if adipocyte conditioned 
media increased PI3K activity, as shown by elevated phospho-Akt protein levels.  In the 
MCF-10CA1 cells treated with adipocyte conditioned media, we saw a significant increase in 
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phospho-Akt expression (1.7-fold).  These results suggest some factor in the adipocyte 
conditioned media is initiating a signaling event at the cell surface, which results in 
activation of PI3K.  Phospho-Akt levels were undetectable in MCF-10A cells with or without 
adipocyte CM treatment.   
Previous data from out lab suggests that uPA expression and activity is positively 
regulated by PI3K, so we next investigated uPA activity in the two cell lines.  While uPA 
activity significantly increases following adipocyte conditioned media treatment in both cell 
lines, uPA activity levels following preadipocyte conditioned media are also elevated, though 
not significantly over control.  The 3.9-fold increase seen in MCF-10CA1 cells supports the 
previous data from the lab showing increased PI3K activity results in increased uPA activity.  
These data suggest adipocyte conditioned media is increasing cell motility through 
modulation of the PA system.  Specifically, adipocyte conditioned media increases PI3K 
activity, resulting in increased uPA activity.   
We next employed a focused PCR array to identify genes related to cancer 
development that were altered following adipocyte treatment.  In MCF-10A cells treated with 
adipocyte conditioned media, we saw down-regulation in several genes, including interferon 
alpha (-2.08-fold), MMP1 (-14.4-fold), MMP2 (-2.28-fold), and thrombospondin (-5.25).  
However, PI3KR1 (+2.37-fold), TIMP3 (+3.14-fold), and uPAR (+2.16-fold) are all 
upregulated.  Interestingly, matrix metalloproteinase (MMP) expression is associated with 
increased metastatic potential in cancer cells [233], while TIMP3 inhibits MMP activation, 
preventing ECM degradation.  The raw data show a very high Ct for TIMP3 in MCF-10A 
cells following both treatments, so it is hard to say if the increase in TIMP3 expression seen 
following adipocyte treatment is enough to mediate a change in vitro.  Although we have an 
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alteration in the machinery involved in ECM degradation, we also saw an upregulation of 
uPAR expression, which has been correlated to increased tumorigenesis and poor prognosis 
in breast cancer patients [68].  We also saw an upregulation of PI3KR1, the regulatory 
subunit of PI3K, which is involved in cell survival, proliferation and migration [234,235].  
While the some of the alterations in gene expression conflict with the in vitro phenotype we 
saw, it is important to get the global view of change within the MCF-10A cells mediated by 
adipocyte conditioned media. 
In contrast to the variations in gene expression seen in MCF-10A cells treated with 
adipocyte conditioned media compared to MCF-10A cells treated with preadipocyte 
conditioned media, we saw less variation in gene expression when we compared MCF-
10CA1 cells treated with adipocyte conditioned media to MCF-10CA1 cells treated with 
preadipocyte conditioned media.  While we did not see the same variation in uPAR and 
PI3KR1 as with MCF-10A cells, we did see a 1.77-fold increase in PAI-1 in MCF-10CA1 
cells treated with adipocyte conditioned media.  This result is in contrast to the uPA activity 
assay result, since elevated PAI-1 levels would most likely decrease uPA activity.  This is 
also in contrast to our understanding of uPA and PAI-1 regulation by PI3K/Akt signaling.  It 
should be noted, in cases such as hypoxia, there is evidence for PI3K/Akt activity positively 
regulate PAI-1 expression [227,236].  Interestingly, we find an almost 2-fold increase in 
Myc, a transcription factor associated with a number of cancers [187,238,239].  Clearly, 
these results are interesting, providing us with a more global understanding of the effects of 
adipocyte conditioned media on these malignant breast epithelial cells.        
Since obesity and excess adiposity is a growing health problem, it is important to try 
and understand the role fat plays in the disease process.  In recent years, surgical intervention 
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in morbidly obese individuals has become more prevalent.  A recent study looked at cancer 
incidences and mortality in morbidly obese individuals who had bariatric surgery and a 
control cohort.  It was reported that 5-years post surgery, 2.03% of individuals were 
diagnosed with cancer, in contrast to 8.49% of control individuals [240].  Another study with 
a much larger cohort reported that 3.85% of patients who had undergone gastric bypass 
developed cancer, while 5.05% of control individuals developed cancer [241].  Both studies 
imply that reduction in adiposity and body mass index reduces the risk of developing cancer 
and cancer related mortality.  There is sufficient data to show obesity and excess adiposity 
has a positive correlation with development of certain types of cancers.  These studies and 
others provide data to suggest reduction of BMI and adiposity reduces the risk of cancer 
development.  Our study was designed to try to understand how adipocytes, specifically from 
the breast, alter the phenotype of breast epithelial cells.  We have shown adipocytes alter 
motility and PI3K/Akt activity in these cells, promoting a more aggressive phenotype.            
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There is a significant amount of research that shows PAI-1 and the PA system are 
intimately linked to cancer pathophysiology.  Intuitively, elevated levels of uPA are 
associated with poor prognosis and decreased survival in breast cancer patients, while 
elevated levels of PAI-1 are also, paradoxically, closely associated with poor patient 
prognosis.  Although the mechanism is not well understood, much of the PAI-1 research in 
the past decade has provided a number of alternative functions for PAI-1.  In addition to 
inhibiting the proteolytic activity of plasminogen activators, PAI-1 has been implicated in 
cell survival and has been shown to have pro-angiogenic effects in cancer cells [148--151].  
This dissertation investigated modulation of the PA system in both breast epithelial cells, 
normal and malignant, and also the surrounding stromal cells, in the form of breast 
adipocytes.   
We began our study by characterizing the PA system in the MCF-10A series of cell 
lines.  These cell lines were chosen because the series includes malignant and preneoplastic 
cell lines, which were derived from the same normal breast epithelial cell line, the MCF-10A 
cells [155,157].  By using cell lines developed from the same parent normal cell, we are able 
to more accurately evaluate molecular and genetic changes in breast cancer disease 
progression in vitro.  We found that expression of the PA system components, specifically 
uPA and PAI-I, were altered in the MCF-10A family members.  In the malignant MCF-
10CA1 cell line, we saw a significant upregulation of uPA protein expression, with a slight 
reduction in PAI-1 protein levels.  This increase in uPA expression in MCF-10CA1 cells 
corresponds to an increase in PI3K/Akt activity.  By inhibiting PI3K, we decreased cell 
motility and uPA protein expression and activity, recapitulating the effects of the uPA 
  
100 
 
inhibitor amiloride.  In characterizing these cell lines, we have described a valuable tool for 
the lab for future breast cancer research into the role of the PA system.   
We next studied the effects of various PPAR-γ ligands on regulation of the PA system 
in MCF-10A and MCF-10CA1 cells.  Using a variety of cell migration assays, we found that 
ciglitazone decreases cell migration in both cell lines, and based on chemotaxis data, these 
effects appear to be independent of PPAR-γ activation.  We show ciglitazone treatment also 
decreases PAI-1 expression, and this effect is not reversed by PPAR-γ antagonism.  It 
appears that the anti-tumor effects of ciglitazone in the MCF-10A family of cells are PPAR-γ 
independent.  Ciglitazone is able to signal through a number of pathways independently of 
PPAR-γ, and it would be important in future studies to tease out the PPAR-γ independent 
mechanism.  Gardner, et al, showed ciglitazone and troglitazone activate p38 MAPK [200].  
Interestingly, p38 MAPK has been shown to induce apoptosis in cancer cells when activated 
by a variety of agents [242].  Because ciglitazone appears to have anti-tumor effects that are 
not the result of PPAR-γ activation, it is important to gain a better understanding of the 
mechanism of action of this drug, and possibly other TZDs commercially available for 
treatment of T2DM.   
Since we have determined that ciglitazone has anti-tumor effects in our breast 
epithelial cell lines, it would be interesting to see if what effect ciglitazone has on PPAR-γ in 
a tumor cell.  By silencing PPAR-γ through siRNA or overexpression of dominant negative 
PPAR-γ, we could investigate any possible differences in cell motility, apoptosis, or 
proliferation following treatment with ciglitazone, when compared to wild-type expression of 
PPAR-γ treated with ciglitazone.   PPAR-γ knock-down would eliminate any confounding 
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effect on signaling events resulting from PPAR-γ activation by ciglitazone.  Given the 
conflicting reports of PI3K/Akt activation and MAPK signaling with PPAR-γ agonists, it 
would be beneficial to eliminate PPAR-γ and see what signaling cascades, if any are altered 
with TZD treatment.  As a correlary, it would be interesting to further study the relationship 
between PI3K/Akt and PPAR-γ by overexpression of constitutively active Akt or siRNA 
silencing of Akt.     
Since we saw a concomitant decrease in cell migration and PAI-1 expresion 
following ciglitazone treatment, we should further investigate ciglitazone effects on cancer 
cell migration in the absence of PAI-1.  In vitro, silencing PAI-1 in MCF-10A or MCF-
10CA1 cells would also add to this story.  Based on the data in Chapter IV, I would expect to 
see less of an effect on cell migration following ciglitazone treatment.  Since ciglitazone and 
PAI-1 have both been implicated in apoptosis, it would be interesting to see what effect on 
apoptosis ciglitazone has in PAI-1 knock-down cells.  Additionally, a PAI-1 knock-out 
mouse model or a PAI-1 overexpressing mouse model could be used to study the effects of 
ciglitazone in vivo [243--245].  In trying to determine if ciglitazone or other TZD drugs have 
any preventative effect on tumor development, the transgenic polyomavirus middle T antigen 
(PymT) under control of the mouse mammary tumor virus long-term repeat promoter 
(MMTV-LTR) mouse line could be used as an in vivo model [246].  These mice develop 
disease similar to human breast cancer, with similar natural history and histology of tumor 
[246].  Based on the in vitro data, I would expect these mice to develop metastatic disease.  
Future studies should be done in a mouse model to validate the anti-tumor effects of 
ciglitazone in breast cancer, and this spontaneous model of metastatic disease would be an 
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ideal method.  It would be crucial to set up a long term dosing experiment and determine the 
effect of TZD therapy in both mouse models (PAI-1-/- and MMTV-PymT).       
Since ω-6 fatty acids are such a prevalent part of the western diet, and based on 
epidemiological studies, they are associated with an increased risk of cancer.  We found that 
the ω-6 fatty acid arachidonic acid increased cell migration in the normal MCF-10A cells, 
while the ω-3 fatty acid docosahexanoic acid had no effect.  Interestingly, following ArA 
treatment we saw an increase in uPA activity on the cell surface, but GW9662 antagonism of 
PPAR-γ did not reverse that effect.  Generation of a dominant negative PPAR-γ 
overexpressing stable MCF-10A cell line would allow future studies to study this and other 
effects of dietary fatty acids.   
Concerning the adipocyte aspect of my project, it would be valuable to determine the 
changes in conditioned media from adipocytes and their precursor cells using a proteomic 
approach.  While we were able to show adipocyte conditioned media increased cell migration 
in both MCF-10A and MCF-10CA1 cells, and we have a global snapshot of alterations in 
gene expression following treatment, we did not identify the factor(s) secreted from the 
adipocytes which mediated these effects.  We hypothesize the excess PAI-1 expressed in 
adipocytes may be playing a role in promoting a more aggressive behavior in the MCF-10A 
and MCF-10CA1 cells.  One experiment of value would be to culture fat pads, from both the 
mammary tissue and the visceral fat depots, from PAI-1 deficient mice and wild-type, collect 
the conditioned media and then perform the motility and gene array assays.  In order to 
distinguish the effect of preadipocytes compared to the adipocytes, these cells could be 
separated using collagenase digestion.  Another experiment that could provide interesting 
information about the effects of epithelial-stromal interactions on tumor development or 
  
103 
 
progression, would be to co-culture adipocytes and breast epithelial cells.  Co-culture models 
have been used to study stomal cell-epithelial cell interactions in a number of cancer types.  
In prostate cancer, co-culture of tumor and stromal cells has been utilized to determine 
effects of normal peripheral zone and transitional zone on tumor growth [247].  In breast 
cancer, it has been shown that direct contact of breast cancer cells with fibroblasts induce 
expression of MMP2, which is important in tumor cell invasion [248].  Shekhar, et al. 
showed using a three-dimensional co-culture model that tumor derived fibroblasts are able to 
support development of tumors from normal and preneoplastic breast epithelial cells [249].  
These studies and others provide useful information about the culture of breast epithelial 
cells with a variety of stromal cell types.  In our model, it would be most interesting to use 
the adipocytes and their precursor cells, and determine if direct contact can alter expression 
of markers of adhesion, angiogenesis, cell survival or apoptosis, or invasion in breast 
epithelial cells.  Finally it would be interesting to compare and contrast the effects of co-
culture models of cultured adipocytes, treated with or without ω-3 fatty acids, ω-6 fatty acids, 
and TZDs, on MCF-10A and MCF-10CA1 cells.   
Therefore, in conclusion of this dissertation, ciglitazone reduces cell migration, 
independently of PPAR-γ and possibly through downregulation of PAI-1; arachidonic acid 
increases cell migration, dependent on PPAR-γ activation, and results in upregulation of uPA 
activity; PAI-1 protein is differentially expressed in adipocytes and their precursor cells, 
dependent on their site of origin; and finally adipocyte conditioned medium increases cell 
migration and uPA activity.  Taken together, these data provide information about a potential 
link between the PA system, obesity and PPAR-γ expression to alter breast cancer 
development and progression.             
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